Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection

STEVEN D. BUCKINGHAM, ANDREW K. JONES, LAURENCE A. BROWN, AND DAVID B. SATTELLE

Medical Research Council Functional Genomics Unit, Department of Physiology Anatomy and Genetics, University of Oxford,
Oxford, United Kingdom

Abstract——Alzheimer's disease (AD), the major contributor to dementia in the elderly, involves accumulation in the brain of extracellular plaques containing the β-amyloid protein (Aβ) and intracellular neurofibrillary tangles of hyperphosphorylated tau protein. AD is also characterized by a loss of neurons, particularly those expressing nicotinic acetylcholine receptors (nAChRs), thereby leading to a reduction in nAChR numbers. The $A\beta_{1-42}$ protein, which is toxic to neurons, is critical to the onset and progression of AD. The discovery of new drug therapies for AD is likely to be accelerated by an improved understanding of the mechanisms whereby Aβ causes neuronal death. We examine the evidence for a role in $A\beta_{1-42}$ toxicity of nAChRs; paradoxically, nAChRs can also protect neurons when activated by nicotinic ligands. Aβ peptides and nicotine differentially activate several intracellular signaling pathways, including the phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog pathway, the extracellular signal-regulated kinase/mitogen-activated protein kinase, and JAK-2/STAT-3 pathways. These pathways control cell death or survival and the secretion of Aβ peptides. We propose that understanding the differential activation of these pathways by nicotine and/or $A\beta_{1-42}$ may offer the prospect of new routes to therapy for AD.

I. Introduction

Alzheimer's disease (AD[1]) is the most common form of dementia in elderly persons. It is a neurodegenerative disease marked by decline in memory and cognitive performance, including deterioration of language as well as defects in visual and motor coordination, and eventual death (for review, see Cummings, 2004). AD also involves loss of neurons, beginning in the entorhinal cortex and later spreading to the neocortex (Braak et al., 2006); early in the disease, nicotinic acetylcholine receptors (nAChRs) are lost (Kadir et al., 2006). AD is characterized pathologically by the occurrence of intracellular neurofibrillary tangles rich in tau protein and extracellular plaques containing amyloid peptides (Price et al., 1991). It has been estimated that in 1997, the disease affected more than 2 million people in the United States alone (Brookmeyer et al., 1998). One study estimated 4.5 million U.S. cases in the year 2000 and predicted that the number will rise 3-fold to 13.2 million by 2050 (Hebert et al., 2003). This may be an overestimate, because it relies on data extrapolated on the basis of education, rather than race, with which AD more strongly correlates, and because many cases of vascular dementia may be mistakenly counted as AD (Grant, 2004). A global study of AD using a Delphi consensus approach indicated that there were 24 million people with dementia worldwide in 2005 and that this will almost double every 20 years, to 42 million by 2020 and 81 million by 2040 (Ferri et al., 2005). The prevalence of AD differs both racially (Froehlich et al., 2001) and geographically (Hendrie et al., 2001; Ferri et al., 2005). Given an estimated per-patient yearly cost of $20,000 (Zhu et al., 2006), even the lowest estimates show that AD is a large-scale and growing social, medical, and economic burden. In such circumstances, finding new routes to therapy for AD is a matter of urgency.

It is generally agreed that the β-amyloid peptide (Aβ) plays an important role in the development of AD. The brains of patients with AD contain deposits of Aβ, and Aβ is toxic to cultured neurons (Kihara et al., 1997a; Yao et al., 2005). In addition, mice transgenically overexpressing Aβ or with mutations that enhance Aβ aggregation show many of the symptoms of AD (Hsiao et al., 1996; van Groen et al., 2006). There is abundant evidence that Aβ also affects cholinergic signaling in the brain. Recent studies indicate that brain nAChRs are not only affected by Aβ but can also initiate signaling pathways that protect against Aβ toxicity (Kihara et al., 1997b; Takada et al., 2003; Arias et al., 2005; Akaike, 2006; Meunier et al., 2006; Dineley, 2007; Liu et al., 2007). Current licensed pharmacological treatments for AD consist largely of three acetylcholinesterase (AChE) inhibitors: rivastigmine, galantamine, and donepezil (Aguglia et al., 2004; Ritchie et al., 2004), although memantine, a blocker of L-glutamate receptors of the *N*-methyl-D-aspartate (NMDA) subtype, is also deployed in late stages of the disease. Interpreting studies on the effectiveness of these compounds is complicated by differences in the measured outcomes (life expectancy, cognitive score, as well as other quality of life measures, often used in various combinations), small sample sizes, and differences in trial methods. There is, however, a consensus that cholinesterase inhibitors perform measurably, but modestly, in slowing the progression of AD (Raina et al., 2008), one meta-analysis estimating their efficacy to amount to saving 2 months per year in the progression of the disease (Trinh et al., 2003). This underscores the importance of cholinergic signaling in AD and offers encouragement that an improved understanding of the roles of nAChRs and their associated signaling proteins in Aβ toxicity may provide clues for the discov-

[1] Abbreviations: AD, Alzheimer's disease; α-BTX, α-bungarotoxin; Aβ, β-amyloid peptide; A-582941, 2-methyl-5-(6-phenyl-pyridazin-3-yl)octahydro-pyrrolo(3,4-*c*)pyrrole; A-85380, 3-(2-azetidinylmethoxy)-pyridine; ABT-418, 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; ACh, acetylcholine; AChE, acetylcholinesterase; AKT, v-akt murine thymoma viral oncogene homolog; APOE, apolipoprotein E type 4; APP, amyloid precursor protein; BAD, BCL2-antagonist of cell death; BAX, Bcl2-associated X protein; BCL2, B-cell chronic lymphocytic leukemia/lymphoma 2; ChAT, choline acetyltransferase; ERK, extracellular signal-regulated kinase; FADK1, focal adhesion kinase; JAK, Janus kinase; JNK, c-jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MCI, mild cognitive impairment; nAChR, nicotinic acetylcholine receptor; NMDA, *N*-methyl-D-aspartate; PET, positron-emission tomography; PI, phosphoinositol; PI3K, phosphoinositol-3-kinase; PIKE, phosphoinositide 3-kinase enhancer; PKC, protein kinase C; PS-1, presenilin-1; RNAi, RNA interference; SPECT, single-photon-emission computed tomography; SRC, v-SRC sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog; STAT, signal transducer and activator of transcription; TNF-α, tumor necrosis factor-α.

ery of new targets for the treatment of AD. Here we review current understanding of the roles in AD played by nAChRs and the downstream signaling cascades to which they are linked.

II. β-Amyloid: Biophysics and Roles in Alzheimer's Disease

The accumulation of plaques consisting of Aβ is one of the histopathological hallmarks of AD. Aβ is the product of serial cleavage of the amyloid precursor protein (APP) first by β and then by γ secretases to yield Aβ peptides of varying lengths, predominantly the 37-, 40-, and 42-residue forms. An increasing ratio of the full-length, 1–42 peptide to the 1–40 form is associated with disease (Kumar-Singh et al., 2006), and mutations underlying familial forms of AD either increase this ratio or increase the amount of Aβ secreted. Aβ peptides belong to a class of natively unfolded proteins and as a consequence can adopt a wide variety of tertiary and quaternary structures in vivo and in vitro, including monomers, oligomers, and fibrils (Luheshi et al., 2007; Roychaudhuri et al., 2009). Early work on AD considered the fibrillar form to be the toxic species. However, a lack of correlation between plaque burden and cognitive score contrasted with a strong positive correlation between total soluble amyloid and cognitive decline pointing to soluble, oligomeric forms as the primary toxic factor (Walsh and Selkoe, 2007). Considerable interest recently focused upon the discovery that Aβ56*, a form whose molecular weight is consistent with its being a dodecamer, can be isolated from the cerebrospinal fluid of transgenic mice expressing human APP and, when injected into rats, rapidly and reversibly induced impaired maze performance (Lesné et al., 2006). However, other naturally occurring oligomeric forms of Aβ are also toxic (Deshpande et al., 2006; Shankar et al., 2008), and evidence is accumulating that the capacity of Aβ, mutant Aβ, or fragments of Aβ to aggregate into oligomers is directly related to toxicity (Luheshi et al., 2007). The biophysics of Aβ aggregation is very complex: aggregation can take different routes to different end points and is highly sensitive to the ionic environment (Roychaudhuri et al., 2009). It is a striking deficit in current research that in physiological experiments designed to determine the mode of action of Aβ, the conditions under which Aβ is prepared and its state of aggregation when tested are not always comparable. This must be borne in mind when reviewing the conflicting reports on the physiology of Aβ action.

III. Nicotinic Acetylcholine Receptors: Structure, Function and Roles in Neuroprotection

nAChRs are ligand-gated ion channels consisting of five subunits that form a central, cation-permeant channel whose opening is gated in response to the binding of the neurotransmitter acetylcholine (ACh). Mammals have 16 nAChR subunit-encoding genes (Fig. 1), five of which function at the neuromuscular junction while the remaining subunits are neuronal. A subclass of α subunits is defined by a pair of adjacent cysteine residues that play a key role in ACh binding. Neuronal nAChRs are generated from α (α2–10) and β (β2–4) subunits (Dani and Bertrand, 2007); the three most abundant brain nAChR subtypes are composed of α7, α4β2, and α3β4 subunits, although nearly 30 brain nAChR subtypes have been described (Lindstrom, 2003).

Several lines of evidence point to a link between brain nAChRs and the development of AD. Biochemical analysis of brains of patients with AD reveals deficits in nAChRs, an increase in butyrylcholinesterase, reduction in ACh, and attenuated activity of cholinergic synthetic [choline acetyltransferase (ChAT)] and inactivating (AChE) enzymes (Bartus et al., 1982; Francis et al., 1999). Butyrylcholinesterase and AChE help terminate ACh signaling by hydrolyzing the transmitter, thereby inactivating it. These findings have led to the cholinergic hypothesis of AD and the development by pharmaceutical companies of therapies targeting cholinergic molecular components, so far mainly targeting the hydrolytic breakdown of ACh by AChE (Arneric et al., 2007). Genetic association studies investigating single nucleotide polymorphisms point to roles for cholinergic signaling components such as the synthetic enzyme ChAT, the inactivating enzyme AChE, and α4β2 nAChRs in AD (Cook et al., 2004, 2005; Vasto et al., 2006). The most vulnerable neurons in AD seem to be those expressing high levels of nAChRs, particularly those containing the α7 subunit (D'Andrea and Nagele, 2006), and the numbers of nAChRs as well as some of their associated proteins change in AD (Martin-Ruiz et al., 1999; Gotti et al., 2006; Sabbagh et al., 2006). In addition, not only have α7 nAChRs been found colocalized with plaques (Wang et al., 2000b) but α7 and α4 subunits are also positively correlated with neurons that accumulate Aβ (Wevers et al., 1999). The putative roles for nAChRs in AD has led to the development of new candidate AD drugs targeting nAChRs (Arneric et al., 2007), some examples of which are shown (Fig. 2).

Thus, although other mechanisms are also involved in the development of AD, there is abundant evidence that defects in cholinergic synaptic transmission and, in particular, nAChR-mediated signaling plays a major role in the disease and are hence the subject of attempts to generate new routes to therapy.

The discovery that nicotine, a ligand acting at nAChRs, and its mimetics can protect neurons against Aβ toxicity (Kihara et al., 1998) is of interest, especially in view of the observation that nicotine also enhances cognition (Rusted et al., 2000). Nicotinic receptors play a particularly prominent role in nicotine protection. The protective effect is blocked by the nicotinic antagonists dihydro-β-erythroidine and mecamylamine (Kihara et al., 2001; Takada-Takatori et al., 2006). In addition to nicotine, donepezil and

FIG. 1. Nicotinic acetylcholine receptors (nAChRs) are pentameric proteins composed of homologous nAChR subunits; they are part of the large superfamily of dicysteine loop (Cys-loop) ligand-gated ion channels, which also includes GABA-gated chloride channels, glycine-gated chloride channels, and serotonin (5-HT)-gated cation channels. The tree shows that mammals possess 16 nAChR genes, whereas an additional subunit type (α8) has been found in chicken and pufferfish. nAChRs are expressed in muscle and in the nervous system, with the most abundant brain types consisting of α7, α4β2, and α3β4. The α7 subunits form homomeric nAChRs, whereas α4β2 and α3β4 form heteromeric receptors. α4β2 heteromers can exist as two distinct stoichiometric arrangements.

rivastigmine, AChE inhibitors currently used as treatments for mild or moderate AD under the brand names of Aricept and Exelon, also protect cultured neuroblastoma cells from the toxic effects of Aβ. Although there is evidence that, in addition to inhibiting AChE, these ligands are also allosteric modulators of nAChRs (Schrattenholz et al., 1996; Coyle et al., 2007), it has not been established whether these AChE inhibitors protect neurons by their actions on α7 nAChRs rather than by simply inhibiting AChE, thereby elevating ACh in the medium. Curiously, although most studies are in agreement that nAChRs need to be activated to mediate their protective effects, mouse cortical neurons are protected by the α7 antagonist methyllycaconitine (Martin et al., 2004), raising the possibility that neuroprotection by α7 agonists may be through desensitization rather than activation of this rapidly desensitizing receptor. This would be consistent with the α7-dependent activation of intracellular signaling pathways by Aβ (Bell et al., 2004), but the opposite effects on cell survival exerted by Aβ and nicotine means that other mechanisms must be sought, such as ligand-specific coupling to downstream signaling pathways.

The action of nicotine may also involve a positive feedback process through the up-regulation of nAChR expression. It is now well established that exposure to nicotine results in increased expression of nAChRs in brain and in cultured cells (for review, see Gentry and Lukas, 2002). Exposure of human neuroblastoma SH-SY5Y cells (which express ganglionic α7 and α3* nAChRs), human TE671/RD

cells, or mouse BC3H-1 cells (which express muscle-type nAChRs) to nicotine for up to 120 h induces a dose- and time-dependent increase in surface ACh and α-bungarotoxin (α-BTX) binding not attributable to changes in mRNA levels (Ke et al., 1998). The nicotine-induced nAChR up-regulation in human SH-EP1 cells heterologously expressing α7 nAChRs is mediated by cAMP and protein kinase C (PKC) (Nuutinen et al., 2006). The effects of long-term nicotine treatment on nAChR expression in rat brain differs for receptors of different subtype composition (most pronounced up-regulation being observed for α4β2 receptors) and for different brain regions (Nguyen et al., 2003). Donepezil, which protects cultured rat cortical neurons, when applied for 4 days resulted in an up-regulation of α4 and α7 nAChRs with the result that donepezil was even more potently protective (Kume et al., 2005). The observation that the effectiveness of various continually applied nicotinic ligands to protect PC12 cells from serum-starvation toxicity correlates well with their power to increase ^{125}I-α-BTX binding (Jonnala and Buccafusco, 2001) suggests that such a positive feedback mechanism may play a significant role in nicotine neuroprotection.

A. Which Nicotinic Acetylcholine Receptor Subunits Mediate Nicotine Neuroprotection?

Nicotine neuroprotection via nAChRs can involve several nAChR subtypes and thus can differ between cell types. Nicotine protection of cultured rat cortical neu-

AZD3480
AstraZeneca
Formerly TC-1734. High selectivity for neuronal $\alpha4\beta2$ nAChRs (Dunbar et al, Psychopharmacology 191, 919-929, 2007), neuroprotective in animal models.

Galantamine
Janssen
Positive allosteric modulator of $\alpha7$ nAChRs and $\alpha4\beta2$ nAChRs and AChE inhibitor

GTS-21
*Comentis, formerly Athenogen*
Agonist of $\alpha7$ nAChRs

Donepezil
Esai, also marketed by Pfizer
Positive allosteric modulator of $\alpha7$ nAChRs and $\alpha4\beta2$ nAChRs and AChE inhibitor

Nefiracetam
Enhances the activity of $\alpha4\beta2$ nicotinic acetylcholine receptors (Narahashi et al, Life Sci 74: 281-291, 2003)
Daiichi Sankyo

Fig. 2. Several drugs either in current use or in clinical trials for the treatment of Alzheimer's disease are active on nicotinic acetylcholine receptors. The manufacturer is shown in italics.

rons against Aβ toxicity is blocked by the $\alpha4\beta2$ antagonist, dihydro-β-erythroidine (Kihara et al., 1998). In SH-SY5Y cells, RNA interference (RNAi) knockdown of $\alpha7$ enhanced Aβ toxicity (Qi et al., 2007), and $\alpha7$ antagonists, but not $\alpha4\beta2$ antagonists, block galantamine protection of cultured rat neurons (Kihara et al., 2004). Donepezil protects cultured rat cortical neurons against Aβ toxicity through both $\alpha7$ and non-$\alpha7$ nAChRs (Takada et al., 2003). It is therefore likely that $\alpha7$ nAChRs are the primary mediators of nicotine neuroprotection, but in some cells, non-$\alpha7$ subtypes are also likely to contribute.

B. Nicotinic Receptor-Mediated Neuroprotection: a Particular Case of a General Prosurvival Mechanism?

Nicotinic neuroprotection against non-Aβ toxicity is also mediated largely through $\alpha7$ nAChRs. $\alpha7$ nAChRs protect PC12 cells against ethanol toxicity (Li et al., 1999a) and from cell death associated with serum depletion (Ren et al., 2005); they protect cultured neurons against glutamate-induced excitotoxicity (Kaneko et al., 1997) and hippocampal slices against oxygen and glucose deprivation (Egea et al., 2007) through the activation of $\alpha7$ nAChRs (Rosa et al., 2006). Nicotine protects SH-SY5Y cells from cell death induced by thapsigargin, an inhibitor of the sarcoplasmic-reticulum calcium pump (Arias et al., 2004). As in the case of amyloid toxicity,

however, non-$\alpha7$ receptors also play roles in nonamyloid toxicity. This can sometimes be cell-type specific. For example, $\alpha4$-specific agonists protect porcine small retinal ganglion cells against L-glutamate toxicity (Thompson et al., 2006), whereas $\alpha7$ nAChRs protect large retinal ganglion cells (Wehrwein et al., 2004) against L-glutamate toxicity. In some cases, only non-$\alpha7$ nAChRs mediate protection. For example, non-$\alpha7$ nAChRs protect cultured nigral dopaminergic neurons from toxicity induced by 1-methyl-4-phenylpyridinium, a neurotoxin that selectively damages nigrostriatal dopaminergic neurons (Jeyarasasingam et al., 2002), and this effect is not mediated by $\alpha7$ receptors. In some cases, non-$\alpha7$ subunits are necessary for neuroprotection. For example, nicotine effectively protects wild-type mice, but not $\alpha4$-knockout mice, against methamphetamine-evoked neurodegeneration (Ryan et al., 2001). It is likely, however, that nicotinic neuroprotection can differ according to the toxic chemical (Gahring et al., 2003).

Protection by nAChRs against apoptosis is not restricted to neurons or neuron-like cells. Hepatic vagus nerve activity has recently been shown to protect hepatocytes from Fas-induced apoptosis via activation of $\alpha7$ nAChRs (Hiramoto et al., 2008). Thus, nicotine seems to exert a general pro-survival action not only on neurons but also on non-neuronal cells, suggesting that the protection offered by nicotine against Aβ

toxicity may therefore simply be the result of a general pro-survival response.

Thus, nAChR-mediated protection of neurons and other cell types against Aβ toxicity is a specific instance of nAChR-mediated protection against several toxic compounds and is effected largely through α7 nAChRs. However, non-α7 nAChRs may also play roles with the relative importance of these two subtypes varying between different tissues, indeed even between different cell types within the same tissue, and depending upon the nature of the toxic challenge.

Given the ability of some nAChR antagonists to exert neuroprotection (Martin et al., 2004) and the fact that nicotine neuroprotection has been achieved at concentrations (approximately millimolar) likely to completely desensitize the receptor, the simplest explanation is that such neuroprotective effects are achieved through the receptor in its desensitized state. Whether such a mechanism is effected through a direct (such as an allosteric) link via signaling between the desensitized receptor and downstream signaling molecules (α7 is known to interact physically with cell signaling molecules) or requires conduction of ions through the receptor, or both, remains to be resolved. However, it should be recalled that Aβ also stabilizes the desensitized state (Dineley et al., 2002), leaving open the question of why Aβ has the opposite effect to nicotine. The answer may reside in differences in the downstream signaling evoked by nicotine and the peptide.

C. Nicotinic Acetylcholine Receptor-Linked Neuroprotection Pathways

1. The Phosphatidylinositol 3-kinase/v-akt Murine Thymoma Viral Oncogene Homolog 1 Pathway. The phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene homolog pathway (PI3K-AKT) is a well established antiapoptotic pathway and has been identified as an important component of nicotine neuroprotection (Kihara et al., 2001). The neuroprotective effects of nicotine are blocked by inhibitors of either PI3K or SRC family kinases, and nicotine evokes an increase in levels of phosphorylated AKT, B-cell chronic lymphocytic leukemia/lymphoma (BCL2), and BCL-2-like protein (Shimohama and Kihara, 2001), which are further downstream in the PI3K/AKT pathway (Fig. 3). Likewise, blocking the PI3K-AKT pathway inhibits the protective effects of AChE inhibitors on neuroblastoma cells or neuronal cells against Aβ (Arias et al., 2005) or L-glutamate neurotoxicity (Takada-Takatori et al., 2006). In all these studies, protection was also inhibited by nAChR blockers, suggesting that these effects are mediated by nAChRs.

How does activating the PI3K pathway by nAChRs protect neurons? One route is through up-regulating the expression of the antiapoptotic protein BCL2. The AD therapeutic AChE inhibitors donepezil, galantamine, and tacrine increase BCL2 expression when applied to cultured neuronal cells (Arias et al., 2004;

Takada-Takatori et al., 2006). In these cells, nicotine promotes cell survival and causes the phosphorylation of the proapoptotic protein Bcl2-associated X protein (BAX), through the PI3K/AKT pathway, reducing the movement of BAX from the cytosol to the mitochondria and inhibiting its apoptotic activity (Xin and Deng, 2005). In lung cancer cells, nicotine also exerts an antiapoptotic effect through activating BCL2-antagonist of cell death (BAD), a process that is inhibited by blockers of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway or the PI3K/AKT pathway (Jin et al., 2004). However, nAChR-mediated neuroprotection may also involve pathways other than those regulating apoptosis. For instance, over-expressing PI3K in *Drosophila melanogaster* neurons in situ results in an increase in functional synapses as well as synaptic sprouting (Martín-Peña et al., 2006). Thus it is possible that nicotine's activation of the PI3K pathway results in increased synaptic stability, and it would be of interest to explore this further in vertebrates. Thus, the evidence suggests that activation of nAChRs activates the PI3K/AKT pathway to favor antiapoptotic pathways and possibly induce synaptogenesis.

2. Nicotinic Acetylcholine Receptors Are Linked to the Phosphatidylinositol 3-kinase/Protein Kinase B Pathway through Tyrosine Kinases. Tyrosine kinases, such as FYN and SRC [v-SRC sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog], may play a key role in linking activation of nAChRs with the PI3K/AKT pathway. The neuroprotective activation of the PI3K/AKT pathway by nicotine involves the tyrosine kinase FYN, which physically interacts with α7 nAChRs, and the p85 subunit of PI3K in rat fetal cortical neurons in culture (Kihara et al., 2001). The role of FYN in Aβ toxicity and nicotine neuroprotection, however, is complex, and the role of tyrosine kinases in mediating nicotine neuroprotection is complicated by the observation that, in addition to being activated by nAChRs, they also regulate nAChRs (Charpantier et al., 2005). It remains to be resolved whether FYN plays a protective or toxic role in the development of AD. FYN expression is increased in brains from patients with AD, specifically in a subset of neurons with elevated hyperphosphorylated tau protein (Shirazi and Wood, 1993), but it is not known whether this increase in FYN contributes to hyperphosphorylation of tau or is a protective response to it. In extracts of human brains from patients with AD, soluble FYN increases with cognitive score and synaptophysin levels and inversely with the tangle count, suggestive of a pro-cognitive role for FYN (Ho et al., 2005). In a microarray study comparing brains from patients with AD with control brains, FYN was found to be significantly up-regulated in AD (Wang et al., 2003a). In this context, it is of interest that FYN has also been shown to activate the PI3K/AKT cascade, thereby inhibiting apoptosis (Tang et al., 2007). Indeed, FYN is required for phos-

FIG. 3. Aβ induces cell death through the activation of nicotinic acetylcholine receptors, as well as through other receptors. Several different signaling cascades, including the ERK/MAPK pathway and the JNK pathway, have been implicated in the actions of Aβ. Aβ also activates AKT and controls the activity of apoptotic proteins, including BAD, BAX, and BCL2. In addition to apoptosis, these pathways also often induce hyperphosphorylation of the tau microtubule protein, providing a link between Aβ-activation of nAChRs and the formation of neurofibrillary tangles. The concentration and time course of Aβ exposure can determine which of these pathways is activated. In addition, several pathways through which nicotine protects cells from Aβ toxicity have been identified, including the JAK-2/STAT-3 pathway, in which nAChR-mediated activation of Janus kinase 2 is transduced into STAT-3 activation; the PI3K/AKT pathway, which results in inhibition of apoptosis; and the ERK/MAPK pathway, which is activated by the Ras/Raf cascade and controls gene expression through c-Myc. There are also direct actions of nicotine on mitochondrial function as well as on the aggregation of Aβ.

phorylation of phosphoinositide 3-kinase enhancer (PIKE), which itself regulates AKT (Fig. 3). PIKE binds to AKT and up-regulates its kinase activity, thereby reducing apoptosis. Phosphorylation protects PIKE from caspase cleavage, hence FYN is antiapoptotic (Tang et al., 2007).

From these findings, it would seem that FYN plays a neuroprotective role. However, FYN may also play a paradoxical role in Aβ toxicity. Indeed, Aβ activates both FYN and the PI3K cascade (Williamson et al., 2002), whereas germline knockout of FYN is neuroprotective in mice (Lambert et al., 1998; Chin et al., 2004). FYN knockout protects mature mouse neurons in organotypic central nervous system cultures (Lambert et al., 1998). Furthermore, inhibitors of SRC, a closely related tyrosine kinase, also prevent nicotinic protection of differentiated PC12 cells against serum-deprivation-induced cell death (Li et al., 1999b), and inhibitors of FYN or Janus kinase-2 (JAK-2) block the neuroprotection against Aβ toxicity of therapeutic AChE inhibitors (Takada-Takatori et al., 2006). FYN physically interacts with and phosphorylates tau protein, and the affinity of this physical interaction is enhanced in AD-associated mutations in tau protein (Bhaskar et al., 2005). Aβ rapidly induces tyrosine phosphorylation of many proteins

(including tau protein) in human and cultured rat cortical neurons (Williamson et al., 2002). This phosphorylation is concomitant with phosphorylation and inactivation of focal adhesion kinase 1 (FADK1, a major downstream target of FYN), is blocked by inhibitors of SRC kinases and PI3K, and involves FYN associating physically with FADK1 (Williamson et al., 2002). The contradictory nature of these results probably stems from the design of these studies, which pool subcellular compartments that might otherwise have separate and different roles for FYN, which is a highly connected hub molecule in the interactome. More research is therefore needed to resolve the complex roles of FYN and FADK1 in nAChR-mediated neuroprotection and as potential therapeutic targets in AD and neuroprotection.

3. Tyrosine Kinase Regulation of Nicotinic Acetylcholine Receptors May Underlie Phytoestrogen Protection. Genistein, a phytoestrogen, protects SH-SY5Y cells (Bang et al., 2004) as well as cultured hippocampal neurons (Zeng et al., 2004) from Aβ toxicity. However, in addition to its action on estrogen receptors, genistein is also a general tyrosine kinase inhibitor that protects cultured neurons from L-glutamate toxicity (Kajta et al., 2007). Genistein enhances the amplitude of ACh responses when human α7 nAChRs are expressed in Xe-

nopus laevis oocytes by inhibiting phosphorylation of the receptor in the intracellular loop (Charpantier et al., 2005; Grønlien et al., 2007) and shows similar actions on $\alpha 7$ nAChRs of rat hippocampal and supraoptic nucleus neurons as well as human SH-SY5Y cells (Charpantier et al., 2005). The potentiating effect of genistein on ACh-evoked responses did not involve a large shift in the EC_{50} for ACh (Grønlien et al., 2007). Thus, although an involvement of estrogen receptors has been demonstrated for the protective action of genistein (Kajta et al., 2007), it is tempting to speculate that the neuroprotective effect of genistein may also involve, at least in part, the enhancement of nAChR function through the inhibition of tyrosine kinase action upon nAChRs. In support of this notion, β-estradiol protects PC12 cells from amyloid toxicity, and this is prevented when $\alpha 7$ nAChRs are blocked with methyllycaconitine (Svensson and Nordberg, 1999).

4. Nicotine Protection and the Janus Kinase-2/Signal Transducer and Activator of Transcription-3 Pathway. JAK-2, another early target in the nicotine neuroprotection pathway that may mediate signaling between the nAChR and the PI3K pathway (Shaw et al., 2002), may link nAChR activation with the JAK/signal transducer and activator of transcription 3 (STAT-3) protective pathway. JAK-2 is also activated by nicotine in non-neuronal cells such as nAChR-bearing keratinocytes (Arredondo et al., 2006). In a microarray study, expression of 8 of 33 JAK/STAT pathway genes was altered when human bronchial epithelial cells were exposed to 5 μM nicotine for 4 to 10 h (Tsai et al., 2006). Thus, the JAK-2/STAT-3 pathway is activated by exposure to nicotine.

Nicotine induced phosphorylation of STAT-3 (signal transducer and activator of transcription 3) in peritoneal macrophages is mediated by an $\alpha 7$-dependent activation of JAK-2, as part of the anti-inflammatory action of vagal nerve stimulation (de Jonge et al., 2005). Short-term nicotine application also induces phosphorylation of p44/42MAPK, p38MAPK, and STAT-3 and was mediated mostly by $\alpha 7$ nAChRs in rat vascular smooth muscle cells (Wada et al., 2007). It is noteworthy that the JAK-2/STAT-3 pathway also mediates the mitogenic effects of insulin, a process recently implicated in AD (Li and Hölscher, 2007). Indeed, in rat vascular smooth muscle cells, insulin and nicotine activate these overlapping pathways (Wada et al., 2007). Nicotine-induced phosphorylation of STAT-3 through activation of $\alpha 7$ has also been demonstrated in human oral keratinocytes (Arredondo et al., 2006).

5. Nicotine Activation of Mitogen-Activated Protein Kinase and JAK/STAT Pathways Leads to Changes in Gene Transcription. Because STAT-3 is a transcription regulator, its activation by nicotine presumably affects the expression of genes, but so far, little is known of which genes are altered in this way or whether this pathway is required for nicotine neuroprotection. Mi-

croarray studies have shown that 24-h incubation in nicotine causes the up-regulation of several genes in SH-SY5Y cells, including ninein (Dunckley and Lukas, 2006), which is known on the basis of a yeast two-hybrid screen to interact with the AD-implicated gene *glycogen synthase kinase 3β* (Hong et al., 2000). However, alterations in expression of typical antiapoptotic genes, such as the *Bcl* family, were not detected. Application of nicotine to rat microglia results in the up-regulated expression of cyclooxygenase-2 and prostaglandin E2 (De Simone et al., 2005). Signaling pathways downstream to the MAPK pathway are similarly well placed to effect changes in gene expression. For example, $\alpha 7$-dependent activation of the MAPK pathway is known to activate c-Myc (Liu et al., 2007), a proto-oncogene whose transcription product sensitizes cells to pro-apoptotic stimuli.

In studies on SH-SY5Y cells and cultured rat hippocampal neurons, nicotine, acting through $\alpha 7$ nAChRs, results in the activation of ERK-1/2 pathways dependent upon calcium and protein kinase A (Dajas-Bailador et al., 2002b). In addition, the $\alpha 7$-specific agonist GTS-21 promotes ERK-1/2 phosphorylation, but not that of c-jun N-terminal kinase (JNK) or p38 (Ren et al., 2005). Furthermore, nicotinic activation of ERK-1/2 promotes survival of cultured murine spinal cord neurons, and the blocking of ERK-1 prevents nicotine's antiapoptotic action (Toborek et al., 2007). Likewise, the $\alpha 7$-specific agonist A-582941 induces phosphorylation of ERK-1/2 in PC12 cells and in mouse brain, and this is completely blocked by the mitogen-activated protein kinase 1 inhibitor SL327 (Bitner et al., 2007). Nicotine also activates ERK in non-neuronal cells such as pancreatic acinar cells (Chowdhury et al., 2007) and vascular smooth muscle cells (Kanda and Watanabe, 2007), although it is not known in those cases which nAChR subtypes are involved. In the cortex and hippocampus of mice, nicotine's inhibition of MAPK (shown by RNAi reduction of $\alpha 7$ expression to be $\alpha 7$-dependent) prevents activation of nuclear factor-κB and c-Myc, also thereby reducing the activity of inducible nitric-oxide synthetase and NO production and decreasing Aβ production (Liu et al., 2007). Paradoxically, Aβ also activates the MAPK pathway through an $\alpha 7$-dependent pathway (Dineley et al., 2001; Bell et al., 2004). In human oral keratinocytes, the Ras/Raf/mitogen-activated protein kinase kinase 1/ERK pathway cooperates with the nicotine activation of the JAK/STAT-3 pathway (Arredondo et al., 2006); the Ras pathway induces STAT-3 up-regulation whereas the JAK/STAT-3 pathway phosphorylates STAT-3.

6. Nicotine Protection and Tumor Necrosis Factor-α Cytokine Signaling. There is evidence that nicotine's neuroprotective effects can be mediated through tumor necrosis factor-α (TNF-α). Application of either nicotine or TNF-α protects cultured mouse embryonic cortical neurons from *N*-methyl-D-aspartate (NMDA) toxicity, but coapplication of both does not. However, coapplica-

tion of both with α-BTX does lead to neuroprotection, suggesting that TNFα and nicotine protect through antagonistic pathways (Carlson et al., 1998; Gahring et al., 2003). Nicotine may regulate the neuroprotective secretion of TNFα by microglia through enhancement of low-level TNF secretion and suppression of lipopolysaccharide-induced TNFα secretion (Suzuki et al., 2006; Park et al., 2007) via α7-dependent activation of JNK and MAPK pathways.

7. Nicotine Protection and Calcium Signaling Pathways. Calcium signaling pathways are involved both in the toxic action of Aβ and in the protection against that toxicity offered by nicotinic ligands. Given that α7 homomeric nAChRs are much more permeable to calcium ions than are most other nAChRs (Bertrand et al., 1993), it is to be expected that nicotinic neuroprotection mediated by nAChRs, notably α7, would depend upon the activation of calcium signaling pathways. ABT-418 is a nicotinic agonist that protects primary rat cortical neurons from glutamate toxicity through its activation of α7 nAChRs, and this is blocked when calcium is removed from the extracellular medium (Donnelly-Roberts et al., 1996). Nicotine protects PC12 cells from cell death resulting from serum depletion through a mechanism that depends upon the function of IP3 receptors, L-type calcium channels, ryanodine receptors, and ERK, suggesting that the protective effect of nicotine is mediated by calcium signaling pathways (Ren et al., 2005). Stevens et al. (2003) showed that calcineurin is involved in nicotine neuroprotection. Aβ, through α7 nAChRs, increases Ca^{2+}, which phosphorylates NMDARs via calcineurin and protein tyrosine phosphatase, nonreceptor type 5 (striatum-enriched) (Snyder et al., 2005).

Recent research interest has focused on the role of calcium dyshomeostasis in AD (Green and LaFerla, 2008); for instance, genetic links with the regulation of cytosolic calcium have been identified (Dreses-Werringloer et al., 2008). Thus nAChRs may provide a link between Aβ and disruption of calcium homeostasis. Short-term application of Aβ to the SH-SY5Y human neuroblastoma cell line results in a rapid increase in intracellular calcium ions that is dependent upon both α3β2 and α7 nAChRs (Dajas-Bailador et al., 2002a). This calcium signal in SH-SY5Y cells arises from three sources: influx of extracellular calcium through voltage-gated calcium channels, release of calcium from intracellular stores, and calcium influx through the α7 receptors. It has been shown that the α7 receptors, but not the α3β2 receptors, specifically trigger calcium release from intracellular stores by activating ryanodine receptors. Such a specific functional coupling of α7 receptors and ryanodine-sensitive stores may provide another site of therapeutic intervention. However, the sustained calcium rise seen in these cells upon prolonged nicotine administration, which is more likely to be of relevance to neuroprotection than short-term responses, is more dependent upon the activation of inositol 1,4,5-triphos-

phate receptors (Dajas-Bailador et al., 2002a), which are also a target for phosphorylation by FYN (Cui et al., 2004). JAK-2, also implicated in the neuroprotective pathway, may play a role in linking nAChR action with calcium signaling, because JAK-2 phosphorylates inositol 1,4,5-triphosphate receptors through its activation of FYN (Wallace et al., 2005). Further research into the relationship between the complex interaction between nAChRs and the calcium signaling machinery is needed to determine the extent to which nicotine exerts its neuroprotective action against Aβ toxicity by counteracting AD-associated disruptions in calcium signaling.

D. Nicotinic Acetylcholine Receptors Mediate β-Amyloid Peptide Actions That Precede Cell Death

The focus of research into the development of AD has shifted in recent years away from toxicity toward earlier events, such as alterations in synaptic function. Consequently, there is mounting evidence that Aβ affects cholinergic signaling independent of its cytotoxic action. For example, Aβ blocks long-term potentiation, a cellular correlate of learning, through activation of JNK and p38MAPK (Wang et al., 2004). APP and APP/presenilin-1 (PS-1) mice do not show neurodegeneration (Irizarry et al., 1997) and yet show several features of AD, including accumulation of plaques and defects in learning (Hsiao et al., 1996), suggesting that many features of AD are not the result of neuronal loss. These animals nonetheless have swollen cholinergic nerve terminals at 12 months, suggesting defective nerve sprouting (Hernandez et al., 2001). It has long been known that cognitive decline in AD correlates well with synaptic loss (Lue et al., 1999), and it has been shown directly that soluble Aβ inhibits synaptic plasticity (Rowan et al., 2004). To date, however, it is not known whether the synaptic actions of Aβ involve nAChRs. Thus, this fertile shift of research focus from toxicity to synaptic mechanisms needs to be matched with similar studies on the nontoxic effects of Aβ on cultured neurons and the effects of nAChR activation on such effects. For example, a recent study has shown that α7-specific ligands rescue the Aβ-induced decrease in neurite outgrowth of cultured mouse neurons (Hu et al., 2007).

E. Apolipoprotein E-ε4, the Product of an Alzheimer's Disease Risk Factor Gene, Activates Nicotinic Acetylcholine Receptors

The apolipoprotein E type 4 allele (APOE-ε4) encodes the APOE lipoprotein, which through its lipid transport function plays a role in lipid metabolism. APOE-ε4 has been found to be a major risk factor for late familial or sporadic AD, with a strong gene-dosage effect such that the number of APOE-ε4 alleles correlated positively with the risk of developing AD and the age of onset (Corder et al., 1993). The APOE-ε4 gene-dose effect was also found to correlate with the loss of nAChR binding sites in patients with AD, as well as a reduced respon-

siveness to the therapeutic AChE inhibitor tacrine (Poirier et al., 1995). Within an AD cohort, APOE-ε4 dose dependently correlates with higher losses of ChAT but not with losses in α4β2 nAChRs (Lai et al., 2006).

There is evidence that ApoE directly interacts with nAChRs. An APOE-derived peptide blocks nAChRs on rat hippocampal slices with a submicromolar affinity, and this action is dependent on an arginine-rich segment of the APOE peptide (Klein and Yakel, 2004). Block of heterologously expressed α7 nAChRs is greater than that for α4β2 or α2β2 nAChRs (Gay et al., 2006). This block of α7 receptors is abolished when α7 Trp55 is mutated to alanine, providing strong evidence that it results from a direct interaction between the peptide and the receptors (Gay et al., 2007), and the effects of other substitutions of Trp55 suggests that this interaction is hydrophobic.

ApoE-ε4, but not ApoE-ε3, disrupts carbachol-stimulated phosphoinositol (PI) hydrolysis and so does Aβ and Aβ/ApoE-ε4 complexes in SH-SY5Y cells (Cedazo-Mínguez and Cowburn, 2001). The effect of Aβ and its ApoE complex on PI hydrolysis were blocked by estrogen, and this disruption was itself blocked by wortmannin, suggesting that PI3K mediates estrogen's effect on PI hydrolysis. Because nAChR activation also protects through activation of the PI3K pathway, it would be of interest to determine whether ApoE-ε4 also disrupts nAChR-activation of PI3K and nAChR-mediated neuroprotection.

F. Nicotinic Acetylcholine Receptors Regulate β-Amyloid Peptide Secretion and Internalization

In addition to Aβ acting upon nAChRs, nAChRs in turn regulate Aβ secretion. Nicotine or epibatidine applied to the human SHEP1 cell line stably transfected with human α4β2 nAChRs and human APP decreases the secretion and intracellular accumulation of Aβ without significantly affecting the APP mRNA, suggesting that these effects are post-translational (Nie et al., 2007). Nicotine stimulates the secretion of βAPP, which is trophic and neuroprotective against Aβ, from PC12 cells through an α7 and calcium-dependent pathway (Kim et al., 1997) as well as increasing the secretion of soluble APP and lowering the Aβ-containing sAPP-γ in rats (Lahiri et al., 2002), again through nAChR-dependent mechanisms. Galantamine, a nAChR potentiator and AChE inhibitor, also increases the secretion of sAPP from human SH-SY5Y neuroblastoma cells (Lenzken et al., 2007) through the activation of nAChRs. It therefore seems that activation of nAChRs shifts the balance of APP processing away from β-amyloidogenic to soluble APP production.

nAChRs may also regulate Aβ internalization. Intracellular accumulation of Aβ by both APOE transport (Gylys et al., 2003; Sadowski et al., 2004) and APOE-independent endocytotic mechanisms (Saavedra et al., 2007) is believed to contribute to cell death (D'Andrea et

al., 2001). The importance of this mechanism to Aβ toxicity is underscored by the recent observation that oligomers, which are the most toxic form of Aβ, are internalized more effectively than the less toxic fibrillar forms (Chafekar et al., 2008). An indication that nAChRs may play a role in Aβ internalization comes from a close inspection of cholinergic neurons in brains from patients with AD, which revealed that neurons with high expression levels of α7 also contained large amounts of intracellular Aβ (Nagele et al., 2002). Addition of Aβ to the culture medium of neuroblastoma cells overexpressing α7 results in more Aβ internalization than in control cells with lower levels of α7 expression (Nagele et al., 2002). It is not clear whether this enhanced uptake is the result of an indirect influence by nAChRs upon internalization or of a direct binding of Aβ to nAChRs. Whatever the mechanism of uptake, it is interesting to note that the signaling pathways evoked by the accumulation of intracellular Aβ resemble those evoked by extracellularly applied Aβ: transgenic rats overexpressing Aβ intraneuronally display elevated levels of phosphorylated ERK2 (Echeverria et al., 2004), as do rat hippocampal slices in response to bath-applied Aβ (Dineley et al., 2001). Again, bath-applied Aβ causes an increase in BAX and a decrease in BCL2 expression in neurons or neuron-like cell lines (Koriyama et al., 2003; Clementi et al., 2006). It is therefore tempting to speculate that the nAChR-dependent activation of signaling pathways by exogenously applied Aβ results from an internalization of Aβ after binding to surface nAChRs. The frequent findings that nAChR antagonists block Aβ-evoked signaling cascades may therefore be due to steric occlusion of the Aβ binding site preventing Aβ internalization. Furthermore, at least some of the reports of an acute partial block of α7 nAChR-mediated responses by Aβ may be the result of Aβ-evoked receptor internalization, resulting in fewer receptors being available at the cell surface. Thus, it seems that nAChRs may play a role in mediating Aβ toxicity through synergistic mechanisms; in addition to possible direct interactions (binding), nAChRs may also result in accelerated cell death through enhancing intracellular Aβ accumulation.

IV. β-Amyloid Peptide Toxicity: Is It Mediated in Part through Nicotinic Acetylcholine Receptors?

Paradoxically, in addition to their neuroprotective action, nAChRs may also partly mediate the toxic action of Aβ. The toxicity of Aβ on SH-SY5Y cells, as measured by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, in which the health of cells is monitored by their ability of cells to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, was significantly impaired when α7 was silenced by RNAi, suggesting that Aβ may exert its toxicity, at least in part, through a pathway that includes α7 nAChRs (Qi et al., 2007). The toxic action of Aβ may involve α7-dependent internalization of amyloid after Aβ binds with high affinity to

the $\alpha 7$ receptor, because the rate of internalization of Aβ in human neuroblastoma SH-SY5Y cells depends upon the level of $\alpha 7$ expression (Nagele et al., 2002). It is noteworthy that this internalization was blocked by α-bungarotoxin, which may indicate that α-bungarotoxin either inhibits binding of Aβ to the $\alpha 7$ receptor (and therefore that Aβ toxicity results from binding of Aβ to $\alpha 7$ nAChRs) or directly inhibits $\alpha 7$ nAChR internalization. However, it has been shown that Aβ_{1-42} binds with high affinity to $\alpha 7$ nAChRs in several different neuronal tissues (Wang et al., 2000a) and displaces α-bungarotoxin binding (Wang et al., 2000a,b) and, rather than inhibiting receptor internalization, α-bungarotoxin enhances internalization of heterologously expressed nAChRs (Kumari et al., 2008). It is also noteworthy that Aβ-induced tau protein phosphorylation in PC12 cells is inhibited not only by $\alpha 7$ agonists, as would be predicted from the role of $\alpha 7$ nAChRs in neuroprotection, but also by α-bungarotoxin (Hu et al., 2008), as might be predicted if the competition by α-bungarotoxin for the Aβ site blocked a direct action of Aβ on nAChRs. It is therefore possible that the toxicity of Aβ is mediated, at least in part, through a direct physical interaction between Aβ and nAChRs.

A. β-Amyloid Peptide Triggers Signaling Cascades via Nicotinic Acetylcholine Receptors

Aβ initiates intracellular signaling cascades via nAChRs (Fig. 3), including the MAPK kinase signaling pathway, resulting in cell death. In hippocampal slices, Aβ activates ERK-2 isoforms of the ERK MAPK. This is blocked by $\alpha 7$ antagonists, suggesting that Aβ evokes the cascade through $\alpha 7$ nAChRs (Dineley et al., 2001). However, an alternative possibility is that activation of nAChRs is permissive for a process in which Aβ does not directly interact with nAChRs: for instance, calcium entry through nAChRs may be required for Aβ toxicity. A microarray comparison of AD and control autopsy brain tissue revealed a down-regulation of MAPK and ERK activator kinase (Loring et al., 2001), indicating possible compensatory gene regulation aimed at reducing Aβ activation of ERK. Which pathway is activated by Aβ depends upon the time of exposure to the amyloid peptide: chronic applications of oligomeric Aβ to hippocampal slice cultures activate the JNK/MAPK pathway but inhibit the ERK/MAPK pathway, whereas short-term applications of Aβ oligomers do not activate JNK (Bell et al., 2004). This may be one of the routes whereby Aβ impairs memory, because ERK-1 and ERK-2 play key roles in the signaling events central to memory (Satoh et al., 2007). In neuroblastoma cells, as well as cultured hippocampal neurons, Aβ activates JNK and ERK, and blocking these prevents Aβ hyperphosphorylating tau protein, as does $\alpha 7$ antisense oligonucleotides or $\alpha 7$ antagonists, suggesting that Aβ may trigger tau protein phosphorylation through ERK and JNK via $\alpha 7$ receptors (Wang et al., 2003b). Aβ leads to phosphorylation of AKT

in cultured mouse neurons through a mechanism that requires $\alpha 7$ nAChRs (Abbott et al., 2008), AKT phosphorylation levels returning to baseline upon prolonged application of Aβ. AKT interacts with BAD to regulate apoptosis and, interestingly, also has many interacting partners in the insulin signaling pathway. Aβ increased activity of BAD, lowered the activity of the antiapoptotic protein BCL2, in rat hippocampal neurons in primary culture (Koriyama et al., 2003) and has been shown to be toxic to human neuroblastoma cells by increasing BAX activity and decreasing BCl-2 activity (Clementi et al., 2006).

B. Does β-Amyloid Act Directly on Nicotinic Acetylcholine Receptors?

The finding that cholinergic neurons degenerate in AD and in AD models does not, of course, imply that this is the result of Aβ acting on nAChRs. For instance, in Aβ-overexpressing mice (PDAPP derived from a heterogeneous background comprising the strains C57BL/6J, DBA/2J, and Swiss-Webster), Aβ seems to target the high-affinity choline transporter (Bales et al., 2006). Most studies arguing for a role of nAChRs in Aβ toxicity or neuroprotection against the toxic actions of Aβ do so on the basis of the block of an observed response by selective nAChR antagonists. Such a block, however, does not necessarily imply that a response is initiated by Aβ binding to nAChRs; it could be that nAChR-evoked signaling, such as calcium entry, is permissive for a separate Aβ pathway. To determine whether Aβ acts upon nAChRs, it is necessary to establish that Aβ binds directly to nAChRs. There are two conflicting reports as to whether Aβ binds with high affinity to $\alpha 7$ nAChRs. In both studies, similar approaches are adopted, yet the findings differ. One study showed high-affinity binding of Aβ at picomolar levels to human $\alpha 7$ nAChRs heterologously expressed in cell lines, based both on the ability of Aβ to displace labeled α-bungarotoxin and the ability of α-bungarotoxin to displace fluorescently labeled Aβ (Wang et al., 2000b). In contrast, Small et al. (2007) found no displacement of α-BTX from SH-SY5Y cells (a cell line very closely related to that used by Wang et al.) by either amyloid or methyllycaconitine. Wang et al. (2000b) also showed similar staining of human AD cortical neurons by $\alpha 7$ and Aβ antibodies in double immunofluorescence, suggesting that in human cortical neurons, $\alpha 7$ and Aβ are closely associated, although such an approach does not prove direct binding. However another study (Small et al., 2007) showed no displacement of labeled α-bungarotoxin from cell lines expressing rat $\alpha 7$ nAChRs. In attempting to resolve the conflicting reports, however, two points should be borne in mind. First, it should be noted that the studies by Wang and colleagues critically showed that Aβ coimmunoprecipitated from human hippocampal membranes with $\alpha 7$ nAChRs, the more natural physiological environment for the receptors. Coimmunoprecipitation is

a more direct demonstration that two proteins interact than double immunofluorescence because the latter lacks the spatial resolution to establish protein binding. Second, Small et al. (2007) found no inhibition by Aβ of α7 nAChRs expressed in oocytes, in contrast to most similar studies. Taken together, the balance of evidence is that Aβ can bind to nAChRs, although we suspect that the most likely explanation for the discrepancy between these key studies and other studies reporting different actions of Aβ on cells lies in the preparation of Aβ, which, as we argue below, is notoriously sensitive to preparation conditions.

Although there is abundant evidence that Aβ can affect nAChR function, studies disagree as to whether Aβ is an antagonist or an agonist at nAChRs (these findings are summarized in Table 1). For example, Aβ has been reported to inhibit single-channel nicotinic receptor currents in rat hippocampal interneurons (Pettit et al., 2001) as well as currents recorded from human α7 receptors heterologously expressed in *Xenopus laevis* oocytes (Tozaki et al., 2002; Grassi et al., 2003; Pym et al., 2005). Aβ, however, activates a mutant (L250T) of the α7 receptor—this mutant conducts current in the desensitized state, indicating that Aβ may exert its antagonistic action through receptor desensitization (Grassi et al., 2003). Aβ action on nAChRs depends on subunit composition; it has been reported to block α7, transiently potentiate α4β2 before blocking, and to have no action on α3β4 (Pym et al., 2005). However, in contrast to its reported transient enhancement when expressed in oocytes, an inhibition of α4β2 has been reported when expressed in human SH-EP1 cells (Wu et al., 2004).

Although many studies report the absence of agonist actions of Aβ, there are reports of Aβ_{1-42} acting as an agonist. Aβ_{1-42} activates heterologously expressed nAChRs (Dineley et al., 2002), and Aβ_{25-35} has been shown to activate non-α7 nAChRs in rat basal forebrain neurons (Fu and Jhamandas, 2003) and to evoke a α7-mediated calcium increases in presynaptic terminals isolated from rat hippocampus and neocortex (Dougherty et al., 2003). Perfusion of soluble Aβ into mouse prefrontal cortex increases dopamine secretion through a mechanism that is blocked by α7 antagonists (Wu et al., 2007). Again, despite numerous reports of a block of α7, one study indicated that Aβ failed to block α7, even though it blocked α4β2, α2β2 and α4α5β2 receptors (Lamb et al., 2005). It has also been observed that although Aβ inhibits recombinant human and mouse α7 nAChRs, transgenic mice overexpressing human Aβ express functional α7 nAChRs, and the amplitude of α7-mediated currents is no different from that of wild-type mice (Spencer et al., 2006).

The conflicting evidence for the nature of Aβ actions on nAChRs clearly needs to be resolved. One possible explanation for these discrepancies might be found in the different concentrations of Aβ used. The most comprehensive study of the effects of Aβ at different concentrations showed that at 10 pM, Aβ evoked an inward current mediated by rat α7 nAChRs expressed in *X. laevis* oocytes, whereas at 100 nM, Aβ blocked nicotine responses through desensitization (Dineley et al., 2002). However, a similar study (Pym et al., 2005) found no evidence of agonist actions of Aβ at 10 pM, although this study used human α7 rather than rat. In addition, complex interactions with receptor-associated proteins and/or intracellular signaling pathways that modulate native nAChRs may also contribute. These may not always be faithfully reproduced in recombinant and cell line studies. Studies differ in the Aβ variant used: at least one study used the more convenient 25–35 fragment (Fu and Jhamandas, 2003), which has been shown to be different in some of its actions from the full-length peptide (Pym et al., 2007). Another intriguing possibility that might explain differences in the findings on the effects of Aβ on nAChRs is that these differences might reflect different splice variants of the nAChR (Severance and Yolken, 2007). A microarray study identified defects in splicing in brains from patients with AD, but nAChRs were not among the gene products highlighted (Heinzen et al., 2007). However, the possibility remains that some differences observed between reports using in vivo preparations may be attributable to different nAChR splice forms in the tissues studied.

The most likely explanation for many of these discrepancies may be differences in the aggregation state of the Aβ used, which is notoriously sensitive to the method of preparation and storage (Teplow, 2006) (see Table 1). Many studies fail to describe how the amyloid was prepared or stored, and others report that they dissolved the amyloid in distilled water. The trifluoroacetic acid salt, the most common form in which commercial preparations are supplied, forms a highly acidic solution, conditions in which aggregation is almost instantaneous (Burdick et al., 1992). This might explain the different findings of Pym et al. (2005), who prepared their Aβ stocks in acetic acid, and Dineley et al. (2002), who prepared theirs in HEPES at pH 8. There is therefore a clear need to resolve the question of different effects of the monomeric, oligomeric, and fibrillar forms of Aβ by systematically examining the effects of carefully prepared solutions on expressed and in situ nAChRs.

V. Loss of Cholinergic Neurons and Nicotinic Acetylcholine Receptors in Alzheimer's Disease

It is clear that AD involves loss of cholinergic neurons in the brain as well as an overall reduction in nAChRs, and it seems that different subunits are differentially up- or down-regulated in AD in different brain regions and different cell types.

Loss of cholinergic neurons has often been demonstrated as lowered ChAT activity in brains of patients with AD. Early post mortem studies indicated a loss of ChAT activity restricted to the neocortex (Slotkin et al.,

TABLE 1
Actions of Aβ on nAChRs

Direct actions of Aβ on nAChRs. The results of actions of Aβ or Aβ fragments on in situ or heterologously expressed nAChRs are summarized, along with a summary of how the Aβ was prepared (if given in the original report), and which concentrations were tested. Both activation and inhibition are reported by different laboratories, even for the same receptor subtype expressed in oocytes.

nAChR	Species	Expression System/Tissue	Aβ Fragment	Aβ Concentration	Aβ Preparation	Actions	Reference
α3β2	Human	X. laevis oocytes	1–40, 1–42	10 nM	5% Acetic acid	No action	Pym et al., 2005
α3β2	Human	X. laevis oocytes	25–35	10 nM	Glacial acetic acid	Inhibits	Pym et al., 2005
α2β2		X. laevis oocytes	1–42			Inhibits	Lamb et al., 2005
α4α5β2		X. laevis oocytes	1–42			Inhibits	Lamb et al., 2005
α4β2	Human	SHEP cell line	1–42	1 nM	Water	Inhibits	Wu et al., 2004
α4β2		X. laevis oocytes	1–42			Inhibits	Lamb et al., 2005
α4β2	Human	X. laevis oocytes	1–40, 1–42	10 nM	5% Acetic acid	Potentiates	Pym et al., 2005
α4β2	Human	X. laevis oocytes	25–35	10 nM	Glacial acetic acid	Inhibits	Pym et al., 2005
α7	Human	Binding to transfected SK-N-MC cells	1–42	N.A.	Not given	Binds with high affinity	Wang et al., 2000
α7	Rat	Binding to transfected SH-SY5Y cells, and to rat brain	1–42	N.A.	DMSO (unaggregated)	No binding	Small et al., 2007
α7	Rat	X. laevis oocytes	1–42	1–100 pM	HEPES pH8	Activates	Dineley et al., 2002
α7	Human	X. laevis oocytes	1–42		DMSO or acetic acid	Inhibits	Grassi et al., 2003
α7	Rat	Presynaptic terminals isolated from rat hippocampus and neocortex	1–42, 12–28	1 pM	Physiological saline	Activates	Dougherty et al., 2003
α7	Mouse	Mouse prefrontal cortex	1–42, 12–28	1 pM–1 nM	Not given	Activates (indirect evidence: increases dopamine secretion)	Wu et al., 2007
α7	Human	X. laevis oocytes	1–42	10 nM	5% acetic acid	Inhibits	Pym et al., 2005
α7	Human	X. laevis oocytes	25–35	10 nM	Glacial acetic acid	Inhibits	Pym et al., 2005
α7		X. laevis oocytes	1–42	?		No inhibition	Lamb et al., 2005
α7 muscle type	Torpedo sp.	X. laevis oocytes	1–42	100 nM	Not given	Inhibits	Tozaki et al., 2002
α7-L248T	Human	X. laevis oocytes	1–42		DMSO or acetic acid	Activates	Grassi et al., 2003
α7-L250T		X. laevis oocytes	1–42			Activates	Dineley et al., 2002
Non-α7	Rat	Rat basal Forebrain neurones	25–35	4 μM	Water	Activates	Fu and Jhamandas, 2003
Non-α7	Rat	Rat basal Forebrain neurons	1–42	100 nM	Water	Activates	Fu and Jhamandas, 2003
Single-channel Nicotinic Receptor currents	Rat	Rat Hippocampal interneurons	1–42	2 μM	Not given	Inhibits	Pettit et al., 2001

DMSO, dimethyl sulfoxide; N.A., not applicable.

1990) and this has been confirmed in more recent studies on frontal lobe and temporal cortex (Lai et al., 2006). It is noteworthy that an increase in ChAT activity in the surviving neurons was interpreted as a possible compensatory mechanism (Slotkin et al., 1990).

AD involves loss of cholinergic cells not only in the cortex but also in subcortical nuclei. Up to 50% loss of neurons and of ChAT activity has been reported at autopsy in the locus ceruleus of brains from patients with AD compared with brains from subjects without AD, whereas no change was observed for adrenergic brainstem nuclei (Strong et al., 1991). A *meta*-analysis of 67 studies on subcortical nuclei involving more than 1800 patients concluded that the most significant loss in cell numbers occurred in the cholinergic nucleus basalis and in the noradrenergic locus ceruleus, whereas fewer cells were lost in the dopaminergic substantia nigra (Lyness et al., 2003). Selective cell loss in the locus ceruleus has also been confirmed in a double-mutant mouse model ([APPswe, PS1dE9]85Dbo/J; PrP promoter) transgenically expressing the Swedish mutant form of the APP and the mutant human APP/PS-1, suggesting that these mutations can contribute to neurodegeneration (O'Neil et al., 2007).

A. Expression of $\alpha4\beta2$ and $\alpha7$ Nicotinic Acetylcholine Receptors Is Reduced in Alzheimer's Disease

A stereological approach, in which specific, identified regions of cortex were excised as a by-product of therapeutic surgery, revealed an approximately 50% decrease in the number of $\alpha7$-containing neurons in the temporal cortices of patients with AD, without overall loss in neuron number (Banerjee et al., 2000). In addition to loss of neurons, there are reports of reduced expression of specific nAChR subtypes, particularly of $\alpha4\beta2$ and $\alpha7$ subunits, in many brain areas in AD. However, because these studies rely on the binding of radiolabeled ligands or the levels of protein expression, it is not always known to what extent this represents a loss of nAChR-expressing cells, reduced receptor numbers in the remaining cells, or both. Binding studies using subtype-selective labeled ligands suggest that $\alpha4\beta2$ receptors are lost in brains from patients with AD (Warpman and Nordberg, 1995; Martin-Ruiz et al., 1999). Regions showing reduced binding levels include the frontal lobe and the temporal cortex (Lai et al., 2006). The use of subunit-specific ($\alpha2$–6 and $\beta2$–4) antibodies to fractionate [3H]epibatidine (a marker for $\alpha4\beta2$ receptors) binding also pointed to a loss of $\alpha4$ and $\beta2$ subunits in the cortex of brains from patients with AD (Gotti et al., 2006). These findings have been confirmed in studies using the recently developed $\alpha4\beta2$-specific radioligand, 5-[125I]-A-85380, which shows reduced expression of $\alpha4\beta2$ in the caudate striatum and entorhinal cortex (Pimlott et al., 2004). This same ligand has also been used to demonstrate loss of $\alpha4\beta2$ in frontal lobe, striatum, right medial temporal lobe, and pons of patients with AD

using single-photon-emission computed tomography (SPECT) (O'Brien et al., 2007). Similar results have been obtained using subtype-specific antibodies. Binding of monoclonal antibodies raised against the $\alpha4$ or the $\alpha7$ subunit, for example, was significantly reduced in post mortem cortices of five patients with AD compared with five patients without AD of similar age (Burghaus et al., 2000). In one study, Western blots confirmed that the greatest reduction was in $\alpha4$ (Guan et al., 2000). Likewise, subunit-specific antibodies reveal a reduced expression of $\alpha4$ but not $\alpha3$ or $\alpha7$ in brains from patients with AD (Martin-Ruiz et al., 1999). One report found no change in $\alpha4$ in frontal cortex or cerebellum, and attenuated levels of $\alpha7$ in these tissues in brains from patients with AD (Engidawork et al., 2001). The loss of $\alpha4$ subunits was suggested to be related to lipid peroxidation, because the loss correlated with the level of peroxidation in the temporal cortex of brains from patients with AD, suggesting that receptor loss may be caused by oxidation of proteins (Yu et al., 2003). Reduction of $\alpha7$ and $\alpha4$ subunits in neurons in patients carrying the Swedish mutation has also been reported (Yu et al., 2005). It is noteworthy that a different pattern of changes in nAChRs is seen in non-neuronal cells; expression levels of $\alpha7$ have been reported to be elevated in astrocytes of brains from patients with AD and in cultured astrocytes (Teaktong et al., 2003; Xiu et al., 2005; Yu et al., 2005). Likewise, studies comparing $\alpha7$ expression in human AD brain and Swedish-mutant mice found enhanced $\alpha7$ expression in astrocytes but decreased expression in neurons compared with controls (Xiao et al., 2006).

The loss of nAChR subunits, as determined by [3H]-epibatidine binding, seems to take place after the transition from mild cognitive impairment (MCI) to AD (Sabbagh et al., 2006), although the loss of epibatidine binding did not correlate with decline in memory, cognitive performance, or with the development of neurofibrillary tangles or plaques (Sabbagh et al., 2001).

Data on changes in levels of $\alpha3$ subunits in AD are complex. An in situ hybridization study of $\alpha3$ failed to find any difference in expression in hippocampus, entorhinal cortex, or thalamus of brains from patients with AD compared with control brains (Terzano et al., 1998). However, a reduction of $\alpha3$ subunits in a Western blot analysis of brains from patients with AD has been observed (Guan et al., 2000), although the loss was not as great as that observed for $\alpha4$ or $\alpha7$ subunits. In addition, $\alpha3$ subunit levels were reduced in the temporal cortex and hippocampus of brains from patients with AD, both smokers and nonsmokers, compared with control subjects (Mousavi et al., 2003). Given the limitations of quantitative results from Western blot studies and that studies on $\alpha3$ may also be complicated by the overall lower levels of expression of $\alpha3$ nAChRs in the brain, more work needs to be done to establish whether $\alpha3$ nAChRs are lost in AD.

Similar effects of $A\beta$ on nAChR expression have been confirmed in studies using cultured cells; $A\beta$ causes a reduced expression of nAChRs in PC12 cells (Guan et al., 2001), and $\alpha4$, $\alpha3$, and $\alpha7$ expression are all increased in cultured rat astrocytes (Xiu et al., 2005). Thus, AD involves opposite expression level changes in astrocytes compared with neurons, and this might reflect different roles for the same nAChR subunit in different cells, in that $\alpha7$ on glial cells is thought to reduce the intensity of the inflammatory response, whereas it is presumed to have both a fast signaling role and a neuroprotective role in neurons. Thus activation of $\alpha7$ nAChRs may protect neurons through two routes: 1) pro-survival signaling intrinsic to neurons and 2) inhibition of the inflammatory response.

Findings from in vivo imaging techniques such as real-time measurements based on positron-emission tomography (PET) offer considerable improvements over traditional in vitro ligand-binding studies. Although new ligands for use in PET, such as $5\text{-}^{125}\text{I-IA-}85380$, still have slow kinetics, they offer improved resolution over $[^{11}\text{C}]$nicotine and lower toxicity than epibatidine analogs. PET imaging has been used to show that loss of $[^{11}\text{C}]$nicotine binding in the frontal and parietal cortices of patients with AD correlates with poorer performance in attention tasks but not with defects in episodic memory or visuospatial tasks (Kadir et al., 2006). The deployment of new ligands in PET and SPECT imaging promises to greatly advance our understanding of how the levels of expression of nAChR subtypes change in AD and in the progression from MCI to AD.

Thus, predominantly $\alpha4$ and $\alpha7$ subunits, and to a lesser extent $\alpha3$ subunits, are lost in AD, although there are tissue-specific differences to this pattern, such as the up-regulation of nAChRs on astrocytes. The $\alpha7$ and $\alpha4$ nAChR subunits are the most abundant in the central nervous system and are therefore more likely to receive research interest, probably leaving less abundant subunits underreported. A significant role for these rarer subunits in AD cannot therefore be excluded. The strikingly different responses often reported for the same subunit in neuronal or glial cells also merits further investigation.

B. Loss of $\alpha4\beta2$ and $\alpha7$ Nicotinic Acetylcholine Receptors Is Not Due to Reduced mRNA

Comparison of the binding of subunit-specific antibodies with the abundance of the subunit mRNA suggests that reduced nAChR subunit expression is not accompanied by reduced levels of the corresponding mRNAs (Hellström-Lindahl et al., 1999; Wevers et al., 1999). This may point to a defect in mRNA translation, although other possibilities, such as mRNA sequestration, cannot be excluded. Intracerebral injection of $A\beta$ into rats resulted in a loss of $\alpha4$ and $\alpha7$ subunits as measured by Western blotting but an increase in $\alpha7$ mRNA (Liu et al., 2008), again suggesting that $A\beta$ directly reduces expression of $\alpha7$ nAChRs through mechanisms other than reduced mRNA

production, although caution should be exercised in interpreting quantitative data from Western blot studies. It is noteworthy that a combined patch-clamp and in situ hybridization study of dissociated human brain tissue (obtained as route-of-access tissue removed during surgery) indicated that neurons near $A\beta$ plaques retained $\alpha4$ and $\alpha7$ mRNA transcripts, whereas these transcripts were absent in neurons burdened with hyperphosphorylated tau protein (Wevers et al., 1999). Such cell-specific differences might be missed in studies that measure levels of mRNA or protein at the tissue level.

The notion that nAChR loss is not due to reduced gene expression is supported by microarray studies, which confirm changes in expression of signaling genes but not those encoding nAChR subunits (Loring et al., 2001; Colangelo et al., 2002; Wang et al., 2003a; Yao et al., 2003). More recent approaches have confirmed this: RNA profiling of isolated neurons from control brains or brains from patients with AD show no evidence for changes in nAChR RNA (Chow et al., 1998; Ginsberg et al., 2000).

Thus, in brains from patients with AD and in neurons responding to exogenously applied $A\beta$, there is a reduction in expression of nAChR subunits, especially $\alpha4$, $\alpha7$, $\beta4$, and possibly $\alpha3$. Although AD may also involve changes in expression of other ligand-gated ion channels—for example, the expression of NMDA receptors (Bi and Sze, 2002; Jacob et al., 2007), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (Jacob et al., 2007), and $\beta3$ GABA receptor subunits are all reduced (Mizukami et al., 1998)—there is abundant evidence of a loss of nAChR subunits in AD possibly caused by the actions of $A\beta$.

C. Animal Alzheimer's Disease Models Show Loss of Nicotinic Acetylcholine Receptors

Findings of reduced nAChRs observed in human patients with AD have been confirmed in some, but not all, animal models of AD (Table 2). Tg2576 mice expressing human $A\beta$ show reduced $[^3\text{H}]$cytisine binding (a label of nAChRs) in the cortex at 17 months after birth (Apelt et al., 2002). In contrast, however, levels of $\alpha7$ or $\alpha4$ subunits were unchanged in double-mutant Swedish APP/PS-1 mice as determined by radiolabeled cytosine ($\alpha4\beta2$) or α-bungarotoxin ($\alpha7$) binding (Marutle et al., 2002). In addition, APP or APP/PS-1 double-mutant mice have normal or even enhanced levels of ChAT and an unchanged cholinergic cell count (Hernandez et al., 2001). However, a double-mutant mouse expressing the Swedish APP and overexpressing human AChE showed enhanced mRNA levels of $\alpha7$ in brain and adrenal medulla, although in brain tissue this enhancement declined with age. In this same mouse, there was no alteration in mRNA levels for $\alpha4$, and an increase in $\alpha3$ has also been observed in the brain and the adrenal medulla (Mousavi and Nordberg, 2006), a pattern similar to that seen in $A\beta$ single-mutant

TABLE 2

Representative list of mouse and invertebrate models used in research on Alzheimer's disease.

There are several animal models of AD, but no single model mimics all the pathological features of AD, although most display locomotor or learning defects.

Name	Transgene	Behavioral Phenotype	Pathology	Reference
Mouse				
hAPP	Human APP with Arctic mutation (E693G) and Swedish mutation (KM670/671N)	Spatial learning deficits at 4–8 months of age in Morris Water Maze	Intracellular $A\beta$ aggregation	Lord et al., 2006
Apps1	APP-KM670/671ML + PS-1-L166P (presenilin)		Cerebral amyloidosis, hyperphosphorylated tau, gliosis, loss of neurons in dentate gyrus but not in neocortex	Radde et al., 2006
TetO-APP Swe/Ind	Chimeric mouse/human APP695 x Tet O: overexpression of $A\beta$	Increased activity	Plaques	Jankowsky et al., 2005
APPSWE (2576)	$A\beta$ K260V, M671L	Impaired learning and memory	Increased $A\beta$ plaques in cortical and limbic areas	Hsiao et al., 1996
PS2APP	Human APPK670N,M671L (Swedish) + Presenilin2-N141I	Cognitive defects, impaired post-tetanic potentiation and paired-pulse responses	Plaques	Richards et al., 2003
hAPPSw/Ind/Arctic	E22G + Swedish and Indiana mutations		Plaques	Cheng et al., 2004
APPSw-NSE	Swedish mutant under neuron-specific pNSE-CAT promoter	Increased escape latencies and escape distance in water maze	Increased $A\beta$, no plaques, increased tau phosphorylation, JNK and p38 activated, COX-2 increased	Hwang et al., 2004
V642I-APP	V642I FAD mutation knocked-in	Deteriorated acquisition of spatial memory but short-term working memory unaffected	No plaques, no NFTs $A\beta_{1-42:1-40}$ ratio increased	Kawasumi et al., 2004
APP-null		Decreased locomotor activity & forelimb grip strength, lower body weight	Reactive gliosis	Zheng et al., 1995
APP Flemish/Dutch	APP-E693Q APP-A692G	Hyperactivity, seizures, male aggression	Plaques, hyperphosphorylated tau	Kumar-Singh et al., 2000
APP London	APP-V642I	Hyperactivity, anxiety, aggression, impaired Morris Water Maze performance		Moechars et al., 1999
PDAPP $_{\text{SwInd}}$(J20)	Various FAD-APP mutations		Increased $A\beta$ levels, plaques	Mucke et al., 2000
PDGF -APP$_{\text{SwInd}}$ line J9	APP V717F		Decreased synaptic terminals, decreased neuronal number, plaques, deficits in neuronal transmission	Hsia et al., 1999
TgCRND8	APP KM670/671NL + V717F	Impaired learning and memory	Plaques, increased $A\beta_{1-42}$	Chishti et al., 2001
C. elegans				
sel-12(ar171)	*sel-12*		Impaired LIN12/GLP1 signaling	Levitan and Greenwald, 1995
	Human $A\beta1$–42 under control of muscle-specific *unc-54* promoter/enhancer	Reduced lifespan, progressive paralysis	$A\beta$ deposits in muscle	Link, 1995
D. melanogaster				
	Presenilin-null	Loss of associative learning in larvae	Loss of paired-pulse plasticity and post-tetanic potentiation	Knight et al., 2007
	Over-expression of human tau	Locomotor impairments	Neuronal death, disrupted axonal transport, altered NMJ morphology	Ubhi et al., 2007
	Presenilin mutations PsnL235P and PsnE280A in PSN deletion background		Slower L-type Ca^{2+} channel deactivation kinetics, impaired synaptic plasticity	Lu et al., 2007
	Wt and mutant human APP		Blistered wing phenotype ($A\beta$ was only released when flies expressed short APP with C terminal fragment fused)	Fossgreen et al., 1998
	Neuronal overexpression of APPL (*Drosophila* APP-like)		Disrupted axonal transport, increased motor neuron synaptic boutons	Torroja et al., 1999
	APPL-deletion	Impaired fast phototaxis		Luo et al., 1992
UAS-tau^{E14}	Mutant human tau		Oxidative stress, cell cycle activation	Dias-Santagata et al., 2007
	Human $A\beta1$–42	Age-dependent learning defects	Neurodegeneration, amyloid deposits	Iijima et al., 2004
	Human $A\beta1$–40	Age-dependent learning defects	No neurodegeneration, no amyloid deposits	Iijima et al., 2004
	BACE + APP + PSEN		Retinal degeneration, amyloid plaques	Greeve et al., 2004
	TAU + GSK3β(shaggy)		Neurodegeneration NFTs	Jackson et al., 2002
	Wt and FAD-mutant human Ab1–42		Retinal degeneration, neurodegeneration plaques	Crowther et al., 2005
	Human $A\beta$	Reduced locomotion	Neurodegeneration	Finelli et al., 2004

mice (Bednar et al., 2002), suggesting that it is not attributable to the human AChE.

VI. Nicotinic Acetylcholine Receptors: Molecular Switches Controlling Survival or Death

Many elements of the pathways involved in either Aβ toxicity or the protective activation of nAChRs have been identified with sufficient consistency to permit a tentative sketch of the interacting pathways involved (Fig. 3) but exercising the appropriate caution necessary when combining findings from different preparations from different phyla and under widely different experimental conditions. There remain a number of important issues to be resolved. 1) The time course of nicotine activation of protective pathways and the effects of long-term exposure to nicotine on nAChRs (especially α7) need to be explored with the aim of developing better models for exploring new therapeutic targets. 2) Many physiological experiments overlook the significance of different aggregation states of Aβ, and very few studies on the effects of exogenous Aβ on the CNS or of nicotine neuroprotection in brains take into account the well documented effects of both of these substances on the vascular system (nicotine, for instance, is angiogenic; some of its protective effects in vivo may be attributable to improved blood supply).

How can nAChRs mediate both the toxic actions of Aβ and the protective actions of nicotine? There must be some way in which these ligands operate different signaling pathways. The simplest explanation might be that Aβ's antagonist actions block the therapeutic effect of nAChR activation. Setting aside the controversy over the actions on nAChRs of Aβ, this explanation is unlikely to offer a full explanation because Aβ alone evokes the ERK/MAPK signaling cascade and causes the phosphorylation of tau proteins through α7 nAChRs (Wang et al., 2003b). Again, both nicotine and Aβ activate the ERK pathway (Dineley et al., 2001; Wang et al., 2003b; Bell et al., 2004) but they do so through different routes (Bell et al., 2004). However, Aβ is toxic to primary cultured neurons from α7-knockout mice, indicating that the α7 receptor is not always required for Aβ toxicity (de Fiebre and de Fiebre, 2003). Thus, either different subpopulations of α7 nAChRs are somehow linked to different signaling pathways or, alternatively, α7 receptors may be differentially coupled to different downstream signaling pathways depending on whether nicotine or Aβ is bound. It must also be borne in mind that α7 receptors in different cellular environments, linked perhaps to different sets of associated proteins, may evoke different signaling cascades.

The question of how two or more signaling pathways can pass through a common node and yet preserve their specificity is relevant to several signaling systems, and several solutions have been proposed. In the case of nicotine and Aβ signaling at nAChRs, spatial separation

of pathways is an unlikely explanation because in the cell-line and cell culture experiments, at least, both nicotine and Aβ have similar access to the receptors. A more engaging explanation is that cross-talk can be prevented using "kinetic insulation" (Behar et al., 2007). In this model, a common signaling node is envisioned with two downstream effectors in which adaptation and response kinetics are different. A rapidly adapting effector acts as a high-pass filter in the time domain and is therefore unaffected by slowly changing inputs, whereas the second effector responds slowly to a stimulus and does not adapt, and therefore acts as a low-pass filter that is unaffected by transient signals. A mathematical model of such a system shows that rapid, transient signals or slow, sustained signals can pass through a common node and specifically activate different signaling pathways (Behar et al., 2007).

The Aβ and nicotine-evoked signaling pathways contain elements that might contribute to such a process. Aβ phosphorylation of AKT in cultured mouse neurons via α7 nAChRs returns to baseline levels upon prolonged application of Aβ (Abbott et al., 2008). Furthermore, the results of activating the same receptors can depend upon the time course of exposure to the agonist and its concentration. The α7 partial agonist 3-(2,4)-dimethoxybenzylidine anabaseine, has a dual effect on PC12 cells depending on concentration and exposure time (Li et al., 1999b). Lower concentrations elevate PKC and protect cells from serum depletion, whereas higher concentrations do not elevate PKC but are toxic. Furthermore, blocking PKC resulted in attenuated neuroprotection, whereas blocking tyrosine kinases attenuated toxicity. Methyllycaconitine blocked neuroprotection only when added 10 min after 3-(2,4)-dimethoxybenzylidine anabaseine addition, but not when added before, a time scale noted by the authors as corresponding to the time scales of α7 activation and desensitization (Li et al., 1999b). Very few studies on nicotine neuroprotection have explored the effects of timing or measured the time course of downstream signals evoked by either nicotine or Aβ, so there is clearly scope for future developments in this area to resolve whether kinetic insulation plays a role in determining the outcome of nAChR activation.

VII. Future Directions

A. Adjusting the Balance between Survival/Death Pathways

It is the consensus view that Aβ targets neurons at least partly via actions on nAChRs and that activation of nAChRs by nicotine protects neurons from Aβ toxicity. It is also clear that nicotinic agonists protect neurons from Aβ toxicity through several intracellular signaling pathways including the ERK/MAPK, PI3K/AKT, and the JAK/STAT pathways. Thus, these pathways could perhaps be exploited as possible sources

for novel therapies. To date, treating AD using anticholinesterases, some of which can both prolong ACh at the synapse and act directly on nAChRs, has had limited success. However, nicotine and Aβ activate similar, but not identical, intracellular signaling pathways, raising the possibility of developing therapies based on diverting the pathways elicited by Aβ toward the survival outcome. Although it is clear that Aβ kills neurons and nicotine protects them against Aβ toxicity, much remains to be resolved to unravel the mechanisms by which death or survival is the outcome. Intracellular signaling initiated by Aβ and nicotine is complex and involves much cross-talk between diverse signaling pathways, arguing for a systems-based approach to understanding precisely how nicotine or Aβ can influence neuronal survival. Such a task could be facilitated by the deployment of mutant suppressor and RNAi screens, as well as the ease of transgene production, afforded by invertebrate model genetic organisms such as *D. melanogaster* and *C. elegans* (Culetto and Sattelle, 2000; Buckingham et al., 2004; Crowther et al., 2004; Jones et al., 2005; Link, 2006). Identifying new components of these pathways offers the prospects of new targets for the treatment of AD. In addition, because α7 receptors are present in human lymphocytes, AD-related alterations in expression of the receptor and/or key associated proteins in these cells may form the basis of a biomarker for early detection of AD or evaluating progression of the disease and responsiveness to drugs (Jones et al., 2006). Furthermore, while the role of nAChR-dependent intracellular signaling has been explored in the context of protection against Aβ toxicity, the roles of the same pathways in promoting synapse function has not been fully explored. The effect of PI3K on promoting synapses in *D. melanogaster* (Martín-Peña et al., 2006), for instance, suggests that this might be a potential target for drugs preventing the early adverse actions of Aβ.

B. Toward Improved Animal and Cell Models

There is scope for the development of improved animal models for AD: in particular, experiments at the cellular level could benefit from improved vertebrate (mouse, rat) and invertebrate (*Caenorhabditis elegans* or *D. melanogaster*) models. Transgenic mouse models include the Tg2576 (Hsiao et al., 1996) and APP23 (Sturchler-Pierrat et al., 1997) models that express human Aβ with the Swedish familial AD mutation, as well as the presenilin models expressing mutated presenilin genes (Table 1). None of the models currently available fully recapitulate all the features of AD, prompting the development of double mutants such as the APP/PSEN models (McGowan et al., 2006). Even these models lack the presence of neurofibrillary tangles. The recent generation of a triple mutant mouse (APP/PSEN/tau) addresses many of the earlier shortcomings (Oddo et al., 2003), but even though the endpoint of the disease

is mimicked, such models are not necessarily instructive on the development of the disease.

The contributions from future studies using mouse AD models will undoubtedly be complemented by the development of new invertebrate models. Although there are limitations with these models accruing from their phylogenetic distance from humans, these limitations are offset by the ease of access, low cost, and speed that they offer. Along with vertebrate cultured cells, they can be deployed in large-scale RNAi studies aimed at identifying genes involved in nicotine neuroprotection and Aβ toxicity. A number of *D. melanogaster* models of AD are available, including several transgenically expressing human Aβ (Crowther et al., 2004, 2005; Iijima et al., 2004) and those mimicking presenilin mutations (Struhl and Greenwald, 1999; Ye et al., 1999). Although these models exhibit neurodegeneration, reduced lifespan, and defective learning, the effects on nAChR expression or on the cholinergic system have not been described. A transgenic *C. elegans* model of AD is available in which microarray studies have shown that expression of three nAChR genes is altered (Link et al., 2003). In this model, the Aβ is expressed in muscle, thus being perhaps a better or at least equally effective model for inclusion body myositis (Rebolledo et al., 2008). A *C. elegans* model in which Aβ is expressed in neurons would be of value in large-scale screens for compounds that rescue the worms or in suppressor/enhancer screens for identifying new genes in the Aβ toxicity pathway.

VIII. Conclusion

The cholinergic hypothesis of AD has spawned 2 decades of research into the roles of nAChRs in this disease, resulting in a widely held view that Aβ can act on, among other targets, nAChRs to result in alterations in synaptic function and eventually cell death. Considerable advances have also been made in our understanding of the roles of the nicotinic cholinergic system in the development of AD. There remain, however, some outstanding gaps in our understanding to be filled and some difficult issues to be resolved. Despite the widely held view, based on block by nicotinic antagonists, that nAChRs mediate neuroprotection, a permissive role for nAChR activation has yet to be ruled out. More seriously, the critical test of the common belief that Aβ exerts at least part of its toxic action through a direct action on nAChRs—the demonstration of high affinity binding to an nAChR—is based on a single report, and further studies are needed. Another serious shortfall in current research into the mechanisms of Aβ toxicity and nicotine neuroprotection stems from our limited understanding of the mechanism of aggregation of the Aβ peptide and its regulation. Aβ aggregation is a complex process, highly sensitive to preparation conditions, so much so that even the same source of material prepared in the same lab can aggregate at different rates

even under apparently identical conditions (Teplow, 2006). Many articles on the actions of Aβ on nAChRs prepare stocks of the protein at low pH and dilute to physiological pH, thus passing through the isoelectric point at which aggregation is maximized (Teplow, 2006; Finder and Glockshuber, 2007). Others promote aggregation by incubating the peptide for several hours at 37°C. To date, despite evidence that oligomers are particularly toxic to neurons and interfere with synaptic transmission and learning, there has been no investigation into how monomers, oligomers and protofibrils interact with nAChRs. The time is therefore ripe for a systematic analysis of the physiological actions of different aggregate forms of Aβ on nAChRs of known composition and on native nAChRs, as well as of the binding of these aggregate forms to nAChRs.

REFERENCES

Abbott JJ, Howlett DR, Francis PT, and Williams RJ (2008) Aβ1–42 modulation of Akt phosphorylation via α7 nAChR and NMDA receptors. *Neurobiol Aging* **29:** 992–1001.

Aguglia E, Onor ML, Saina M, and Maso E (2004) An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. *Curr Med Res Opin* **20:**1747–1752.

Akaike A (2006) Preclinical evidence of neuroprotection by cholinesterase inhibitors. *Alzheimer Dis Assoc Disord* **20:**S8–S11.

Apelt J, Kumar A, and Schliebs R (2002) Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human β-amyloid precursor protein. *Brain Res* **953:**17–30.

Arias E, Alés E, Gabilan NH, Cano-Abad MF, Villarroya M, García AG, and López MG (2004) Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. *Neuropharmacology* **46:**103–114.

Arias E, Gallego-Sandín S, Villarroya M, García AG, and López MG (2005) Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. *J Pharmacol Exp Ther* **315:**1346–1353.

Arneric SP, Holladay M, and Williams M (2007) Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. *Biochem Pharmacol* **74:** 1092–1101.

Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, and Grando SA (2006) Receptor-mediated tobacco toxicity: Cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of α7 nicotinic receptor in oral keratinocytes. *FASEB J* **20:**2093–2101.

Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, and Nomikos GG (2006) Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody. *J Clin Invest* **116:**825–832.

Banerjee C, Nyengaard JR, Wevers A, de Vos RA, Jansen Steur EN, Lindstrom J, Pilz K, Nowacki S, Bloch W, and Schröder H (2000) Cellular expression of α7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease–a stereological approach. *Neurobiol Dis* **7:**666–672.

Bang OY, Hong HS, Kim DH, Kim H, Boo JH, Huh K, and Mook-Jung I (2004) Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. *Neurobiol Dis* **16:**21–28.

Bartus RT, Dean RL 3rd, Beer B, and Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. *Science* **217:**408–414.

Bednar I, Paterson D, Marutle A, Pham TM, Svedberg M, Hellström-Lindahl E, Mousavi M, Court J, Morris C, Perry E, et al. (2002) Selective nicotinic receptor consequences in APP(SWE) transgenic mice. *Mol Cell Neurosci* **20:**354–365.

Behar M, Dohlman HG, and Elston TC (2007) Kinetic insulation as an effective mechanism for achieving pathway specificity in intracellular signaling networks. *Proc Natl Acad Sci U S A* **104:**16146–16151.

Bell KA, O'Riordan KJ, Sweatt JD, and Dineley KT (2004) MAPK recruitment by β-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. *J Neurochem* **91:**349–361.

Bertrand D, Galzi JL, Devillers-Thiéry A, Bertrand S, and Changeux JP (1993) Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor. *Proc Natl Acad Sci U S A* **90:**6971–6975.

Bhaskar K, Yen SH, and Lee G (2005) Disease-related modifications in tau affect the interaction between Fyn and Tau. *J Biol Chem* **280:**35119–35125.

Bi H and Sze CI (2002) N-Methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. *J Neurol Sci* **200:**11–18.

Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, et al. (2007) Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates

with activation of ERK1/2 and CREB phosphorylation pathways. *J Neurosci* **27:** 10578–10587.

Braak H, Rub U, Schultz C, and Del Tredici K (2006) Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. *J Alzheimers Dis* **9:**35–44.

Brookmeyer R, Gray S, and Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. *Am J Public Health* **88:**1337–1342.

Buckingham SD, Esmaeili B, Wood M, and Sattelle DB (2004) RNA interference: from model organisms towards therapy for neural and neuromuscular disorders. *Hum Mol Genet* **13:**R275–R288.

Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, and Glabe C (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. *J Biol Chem* **267:**546–554.

Burghaus L, Schütz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, and Schröder H (2000) Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. *Mol Brain Res* **76:**385–388.

Carlson NG, Bacchi A, Rogers SW, and Gahring LC (1998) Nicotine blocks TNF-alpha-mediated neuroprotection to NMDA by an alpha-bungarotoxin-sensitive pathway. *J Neurobiol* **35:**29–36.

Cedazo-Mínguez A and Cowburn RF (2001) Apolipoprotein E isoform-specific disruption of phosphoinositide hydrolysis: protection by estrogen and glutathione. *FEBS Lett* **504:**45–49.

Chafekar SM, Baas F, and Scheper W (2008) Oligomer-specific Aβ toxicity in cell models is mediated by selective uptake. *Biochim Biophys Acta* **1782:**523–531.

Charpantier E, Wiesner A, Huh KH, Ogier R, Hoda JC, Allaman G, Raggenbass M, Feuerbach D, Bertrand D, and Fuhrer C (2005) α7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. *J Neurosci* **25:**9836–9849.

Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, and Mucke L (2004) Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. *Nat Med* **10:**90–1192.

Chin J, Palop JJ, Yu GQ, Kojima N, Masliah E, and Mucke L (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. *J Neurosci* **24:**4692–4697.

Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser PE, Carlson GA, George-Hyslop PS, and Westaway D (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. *J Biol Chem* **276:**21562–21570.

Chow N, Cox C, Callahan LM, Weimer JM, Guo L, and Coleman PD (1998) Expression profiles of multiple genes in single neurons of Alzheimer's disease. *Proc Natl Acad Sci U S A* **95:**9620–9625.

Chowdhury P, Bose C, and Udupa KB (2007) Nicotine-induced proliferation of isolated rat pancreatic acinar cells: effect on cell signalling and function. *Cell Prolif* **40:**125–141.

Clementi ME, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, Giardina B, and Misiti F (2006) Alzheimer's amyloid beta-peptide (1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. *Biochem Biophys Res Commun* **342:**206–213.

Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, and Lukiw WJ (2002) Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: Transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. *J Neurosci Res* **70:**462–473.

Cook LJ, Ho LW, Taylor AE, Brayne C, Evans JG, Xuereb J, Cairns NJ, Pritchard A, Lemmon H, Mann D, et al. (2004) Candidate gene association studies of the α 4 (CHRNA4) and β2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. *Neurosci Lett* **358:**142–146.

Cook LJ, Ho LW, Wang L, Terrenoire E, Brayne C, Evans JG, Xuereb J, Cairns NJ, Turic D, Hollingworth P, et al. (2005) Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. *Am J Med Genet B Neuropsychiatr Genet* **132:**5–8.

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, and Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261:**921–923.

Coyle JT, Geerts H, Sorra K, and Amatniek J (2007) Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. *J Alzheimers Dis* **11:**491–507.

Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, Gubb DC, and Lomas DA (2005) Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a *Drosophila* model of Alzheimer's disease. *Neuroscience* **132:**123–135.

Crowther DC, Kinghorn KJ, Page R, and Lomas DA (2004) Therapeutic targets from a *Drosophila* model of Alzheimer's disease. *Curr Opin Pharmacol* **4:**513–516.

Cui J, Matkovich SJ, deSouza N, Li S, Rosemblit N, and Marks AR (2004) Regulation of the type 1 inositol 1,4,5-trisphosphate receptor by phosphorylation at tyrosine 353. *J Biol Chem* **279:**16311–16316.

Culetto E and Sattelle DB (2000) A role for *Caenorhabditis elegans* in understanding the function and interactions of human disease genes. *Hum Mol Genet* **9:**869–877.

Cummings JL (2004) Alzheimer's disease. *N Engl J Med* **351:**56–67.

D'Andrea MR, Nagele RG, Wang HY, Peterson PA, and Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. *Histopathology* **38:**120–134.

Dajas-Bailador FA, Mogg AJ, and Wonnacott S (2002a) Intracellular Ca^{2+} signals evoked by stimulation of nicotinic acetylcholine receptors in SH-SY5Y cells: contribution of voltage-operated Ca^{2+} channels and Ca^{2+} stores. *J Neurochem* **81:** 606–614.

Dajas-Bailador FA, Soliakov L, and Wonnacott S (2002b) Nicotine activates the

extracellular signal-regulated kinase 1/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. *J Neurochem* **80:**520–530.

D'Andrea MR and Nagele RG (2006) Targeting the α7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. *Curr Pharm Des* **12:**677–684.

Dani JA and Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu Rev Pharmacol Toxicol* **47:**699–729

de Fiebre NC and de Fiebre CM (2003) α7 Nicotinic acetylcholine receptor-mediated protection against ethanol-induced neurotoxicity. *Alcohol* **31:**149–153.

de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van den Wijngaard RM, et al. (2005) Stimulation of the vagus nerve attenuates macrophage activation by activating the JAK2-STAT3 signaling pathway. *Nat Immunol* **6:**844–851.

De Simone R, Ajmone-Cat MA, Carnevale D, and Minghetti L (2005) Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. *J Neuroinflammation* **2:**4.

Deshpande A, Mina E, Glabe C, and Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. *J Neurosci* **26:**6011–6018.

Dias-Santagata D, Fulga TA, Duttaroy A, and Feany MB (2007) Oxidative stress mediates tau-induced neurodegeneration in *Drosophila*. *J Clin Invest* **117:**236–245.

Dineley KT (2007) Beta-amyloid peptide–nicotinic acetylcholine receptor interaction: two faces of health and disease. *Front Biosci* **12:**5030–5038.

Dineley KT, Bell KA, Bui D, and Sweatt JD (2002) βAmyloid peptide activates α7 nicotinic acetylcholine receptors expressed in *Xenopus* oocytes. *J Biol Chem* **277:** 25056–25061.

Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, and Sweatt JD (2001) β-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. *J Neurosci* **21:**4125–4133.

Donnelly-Roberts DL, Xue IC, Arneric SP, and Sullivan JP (1996) In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. *Brain Res* **719:**36–44.

Dougherty JJ, Wu J, and Nichols RA (2003) β-Amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. *J Neurosci* **23:**6740–6747.

Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A, Jain A, Koppel J, Rovelet-Lecrux A, Hannequin D, et al. (2008) A polymorphism in CALHM1 influences Ca^{2+} homeostasis, Aβ levels, and Alzheimer's disease risk. *Cell* **133:**1149–1161.

Dunckley T and Lukas RJ (2006) Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. *Brain Res* **1116:**39–49.

Echeverria V, Ducatenzeiler A, Dowd E, Jänne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, et al. (2004) Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the β-amyloid peptide intracellularly in hippocampal and cortical neurons. *Neuroscience* **129:**583–592.

Egea J, Rosa AO, Sobrado M, Gandía L, López MG, and García AG (2007) Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in α7 nicotinic receptor knockout mice. *Neuroscience* **145:** 866–872.

Engidawork E, Gulesserian T, Balic N, Cairns N, and Lubec G (2001) Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer's disease. *J Neural Transm Suppl* **(61):**211–222.

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, et al. (2005) Global prevalence of dementia: a Delphi consensus study. *Lancet* **366:**2112–2117.

Finder VH and Glockshuber R (2007) Amyloid-β aggregation. *Neurodegener Dis* **4:**13–27.

Finelli A, Kelkar A, Song HJ, Yang H, and Konsolaki M (2004) A model for studying Alzheimer's Abeta42-induced toxicity in *Drosophila melanogaster*. *Mol Cell Neurosci* **26:**365–375.

Fossgreen A, Brückner B, Czech C, Masters CL, Beyreuther K, and Paro R (1998) Transgenic *Drosophila* expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. *Proc Natl Acad Sci U S A* **95:**13703–13708.

Francis PT, Palmer AM, Snape M, and Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. *J Neurol Neurosurg Psychiatry* **66:** 137–147.

Froehlich TE, Bogardus ST Jr, and Inouye SK (2001) Dementia and race: are there differences between African Americans and Caucasians? *J Am Geriatr Soc* **49:**477–484.

Fu W and Jhamandas JH (2003) β-Amyloid peptide activates non-α7 nicotinic acetylcholine receptors in rat basal forebrain neurons. *J Neurophysiol* **90:**3130–3136.

Gahring LC, Meyer EL, and Rogers SW (2003) Nicotine-induced neuroprotection against *N*-methyl-D-aspartic acid or β-amyloid peptide occur through independent mechanisms distinguished by pro-inflammatory cytokines. *J Neurochem* **87:**1125–1136.

Gay EA, Bienstock RJ, Lamb PW, and Yakel JL (2007) Structural determinates for apolipoprotein E-derived peptide interaction with the α7 nicotinic acetylcholine receptor. *Mol Pharmacol* **72:**838–849.

Gay EA, Klein RC, and Yakel JL (2006) Apolipoprotein E-derived peptides block α7 neuronal nicotinic acetylcholine receptors expressed in *Xenopus* oocytes. *J Pharmacol Exp Ther* **316:**835–842.

Gentry CL and Lukas RJ (2002) Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. *Curr Drug Targets CNS Neurol Disord* **1:**359–385.

Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, and Trojanowski JQ (2000) Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. *Ann Neurol* **48:**77–87.

Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Longhi R, Riganti L, Gaimarri A, McKeith IG, Perry RH, et al. (2006) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. *Neurobiol Dis* **23:**481–489.

Grant WB (2004) Year 2000 prevalence of Alzheimer disease in the united states. *Arch Neurol* **61:**802–803; author reply 803.

Grassi F, Palma E, Tonini R, Amici M, Ballivet M, and Eusebi F (2003) Amyloid β1–42 peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors. *J Physiol* **547:**147–157.

Green KN and LaFerla FM (2008) Linking calcium to Aβ and Alzheimer's disease. *Neuron* **59:**190–194.

Greeve I, Kretzschmar D, Tschäpe JA, Beyn A, Brellinger C, Schweizer M, Nitsch RM, and Reifegerste R (2004) Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic *Drosophila*. *J Neurosci* **24:**3899–3906.

Grønlien JH, Håkerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, and Malysz J (2007) Distinct profiles of α7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. *Mol Pharmacol* **72:**715–724.

Guan ZZ, Miao H, Tian JY, Unger C, Nordberg A, and Zhang X (2001) Suppressed expression of nicotinic acetylcholine receptors by nanomolar β-amyloid peptides in PC12 cells. *J Neural Transm* **108:**1417–1433.

Guan ZZ, Zhang X, Ravid R, and Nordberg A (2000) Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. *J Neurochem* **74:**237–243.

Gylys KH, Fein JA, Tan AM, and Cole GM (2003) Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. *J Neurochem* **84:**1442–1451.

Hebert LE, Scherr PA, Bienias JL, Bennett DA, and Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. *Arch Neurol* **60:**1119–1122.

Heinzen EL, Yoon W, Weale ME, Sen A, Wood NW, Burke JR, Welsh-Bohmer KA, Hulette CM, Sisodiya SM, and Goldstein DB (2007) Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's disease. *Genome Biol* **8:**R32.

Hellström-Lindahl E, Mousavi M, Zhang X, Ravid R, and Nordberg A (1999) Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. *Brain Res Mol Brain Res* **66:**94–103.

Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, et al. (2001) Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. *JAMA* **285:**739–747.

Hernandez D, Sugaya K, Qu T, McGowan E, Duff K, and McKinney M (2001) Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. *Neuroreport* **12:** 1377–1384.

Hiramoto T, Chida Y, Sonoda J, Yoshihara K, Sudo N, and Kubo C (2008) The hepatic vagus nerve attenuates fas-induced apoptosis in the mouse liver via alpha7 nicotinic acetylcholine receptor. *Gastroenterology* **134:**2122–2131.

Ho GJ, Hashimoto M, Adame A, Izu M, Alford MF, Thal LJ, Hansen LA, and Masliah E (2005) Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. *Neurobiol Aging* **26:**625–635.

Hong YR, Chen CH, Chang JH, Wang S, Sy WD, Chou CK, and Howng SL (2000) Cloning and characterization of a novel human ninein protein that interacts with the glycogen synthase kinase 3β. *Biochim Biophys Acta* **1492:**513–516.

Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, and Mucke L (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. *Proc Natl Acad Sci U S A* **96:**3228–3233.

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, and Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. *Science* **274:**99–102.

Hu M, Schurdak ME, Puttfarcken PS, El Kouhen R, Gopalakrishnan M, and Li J (2007) High content screen microscopy analysis of $A\beta_{1-42}$-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of α7 neuronal nicotinic acetylcholine receptor ligands. *Brain Res* **1151:**227–235.

Hu M, Waring JF, Gopalakrishnan M, and Li J (2008) Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1–42)-induced tau phosphorylation in PC12 cells. *J Neurochem* **106:**1371–1377.

Hwang DY, Cho JS, Lee SH, Chae KR, Lim HJ, Min SH, Seo SJ, Song YS, Song CW, Paik SG, Sheen YY, and Kim YK (2004) Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw. *Exp Neurol* **186:**20–32.

Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, and Zhong Y (2004) Dissecting the pathological effects of human Abeta40 and Abeta42 in *Drosophila*: a potential model for Alzheimer's disease. *Proc Natl Acad Sci U S A* **101:**6623–6628.

Irizarry MC, McNamara M, Fedorchak K, Hsiao K, and Hyman BT (1997) APPSw transgenic mice develop age-related Abeta deposits and neuropil abnormalities, but no neuronal loss in CA1. *J Neuropathol Exp Neurol* **56:**965–973.

Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, and Geschwind DH (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in *Drosophila*. *Neuron* **34:** 509–519.

Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, and Grünblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. *J Alzheimers Dis* **11:**97–116.

Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, and Borchelt DR (2005) Persistent

amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. *PLoS Med* **2:**e355.

Jeyarasasingam G, Tompkins L, and Quik M (2002) Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. *Neuroscience* **109:**275–285.

Jin Z, Gao F, Flagg T, and Deng X (2004) Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. *J Biol Chem* **279:**23837–23844.

Jones AK, Buckingham SD, and Sattelle DB (2005) Chemistry-to-gene screens in *Caenorhabditis elegans. Nat Rev Drug Discov* **4:**321–330.

Jones IW, Westmacott A, Chan E, Jones RW, Dineley K, O'Neill MJ, and Wonnacott S (2006) α7 nicotinic acetylcholine receptor expression in Alzheimer's disease: receptor densities in brain regions of the APP(SWE) mouse model and in human peripheral blood lymphocytes. *J Mol Neurosci* **30:**83–84.

Jonnala RR and Buccafusco JJ (2001) Relationship between the increased cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. *J Neurosci Res* **66:**565–572.

Kadir A, Almkvist O, Wall A, Långström B, and Nordberg A (2006) PET imaging of cortical ^{11}C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. *Psychopharmacology* (*Berl*) **188:**509–520.

Kajta M, Domin H, Grynkiewicz G, and Lason W (2007) Genistein inhibits glutamate-induced apoptotic processes in primary neuronal cell cultures: An involvement of aryl hydrocarbon receptor and estrogen receptor/glycogen synthase kinase-3β intracellular signaling pathway. *Neuroscience* **145:**592–604.

Kanda Y and Watanabe Y (2007) Nicotine-induced vascular endothelial growth factor release via the EGFR-ERK pathway in rat vascular smooth muscle cells. *Life Sci* **80:**1409–1414.

Kaneko S, Maeda T, Kume T, Kochiyama H, Akaike A, Shimohama S, and Kimura J (1997) Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. *Brain Res* **765:**135–140.

Kawasumi M, Chiba T, Yamada M, Miyamae-Kaneko M, Matsuoka M, Nakahara J, Tomita T, Iwatsubo T, Kato S, Aiso S, Nishimoto I, and Kouyama K (2004) Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice. *Eur J Neurosci* **19:**2826–2838.

Ke L, Eisenhour CM, Bencherif M, and Lukas RJ (1998) Effects of chronic nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of nicotine treatment. *J Pharmacol Exp Ther* **286:**825–840.

Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, and Shimohama S (2004) Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. *Biochem Biophys Res Commun* **325:**976–982.

Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, and Akaike A (2001) α7 Nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block a β-amyloid-induced neurotoxicity. *J Biol Chem* **276:**13541–13546.

Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, and Akaike A (1997a) Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. *Ann Neurol* **42:**159–163.

Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, and Akaike A (1997b) Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. *Ann Neurol* **42:**159–163.

Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, and Akaike A (1998) Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity. *Brain Res* **792:**331–334.

Kim SH, Kim YK, Jeong SJ, Haass C, Kim YH, and Suh YH (1997) Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. *Mol Pharmacol* **52:**430–436.

Klein RC and Yakel JL (2004) Inhibition of nicotinic acetylcholine receptors by apolipoprotein E-derived peptides in rat hippocampal slices. *Neuroscience* **127:**563–567.

Knight D, Iliadi K, Charlton MP, Atwood HL, and Boulianne GL (2007) Presynaptic plasticity and associative learning are impaired in a *Drosophila* presenilin null mutant. *Dev Neurobiol* **67:**1598–1613.

Koriyama Y, Chiba K, and Mohri T (2003) Propentofylline protects β-amyloid protein-induced apoptosis in cultured rat hippocampal neurons. *European Journal of Pharmacology* **458:**235–241.

Kumari S, Borroni V, Chaudhry A, Chanda B, Massol R, Mayor S, and Barrantes FJ (2008) Nicotinic acetylcholine receptor is internalized via a Rac-dependent, dynamin-independent endocytic pathway. *J Cell Biol* **181:**1179–1193.

Kumar-Singh S, Dewachter I, Moechars D, Lübke U, De Jonghe C, Ceuterick C, Checler F, Naidu A, Cordell B, Cras P, Van Broeckhoven C, and Van Leuven F (2000) Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. *Neurobiol Dis* **7:**9–22.

Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut B, Wang R, and Van Broeckhoven C (2006) Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. *Hum Mutat* **27:**686–695.

Kume T, Sugimoto M, Takada Y, Yamaguchi T, Yonezawa A, Katsuki H, Sugimoto H, and Akaike A (2005) Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. *Eur J Pharmacol* **527:**77–85.

Lahiri DK, Utsuki T, Chen D, Farlow MR, Shoaib M, Ingram DK, and Greig NH (2002) Nicotine reduces the secretion of Alzheimer's beta-amyloid precursor protein containing β-amyloid peptide in the rat without altering synaptic proteins. *Ann N Y Acad Sci* **965:**364–372.

Lai MK, Tsang SW, Garcia-Alloza M, Minger SL, Nicoll JA, Esiri MM, Wong PT, Chen CP, Ramírez MJ, and Francis PT (2006) Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. *Neurobiol Dis* **22:**555–561.

Lamb PW, Melton MA, and Yakel JL (2005) Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in *Xenopus* oocytes by β-amyloid1–42 peptide. *J Mol Neurosci* **27:**13–21.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al. (1998) Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A* **95:**6448–6453.

Lenzken SC, Lanni C, Govoni S, Lucchelli A, Schettini G, and Racchi M (2007) Nicotinic component of galantamine in the regulation of amyloid precursor protein processing. *Chem Biol Interact* **165:**138–145.

Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, and Ashe KH (2006) A specific amyloid-β protein assembly in the brain impairs memory. *Nature* **440:**352–357.

Levitan D and Greenwald I (1995) Facilitation of lin-12-mediated signalling by sel-12, a *Caenorhabditis elegans* S182 Alzheimer's disease gene. *Nature* **377:**351–354.

Li L and Hölscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: A review. *Brain Res Rev* **56:**384–402.

Li Y, King MA, Grimes J, Smith N, de Fiebre CM, and Meyer EM (1999a) α7 Nicotinic receptor mediated protection against ethanol-induced cytotoxicity in PC12 cells. *Brain Res* **816:**225–228.

Li Y, Papke RL, He YJ, Millard WJ, and Meyer EM (1999b) Characterization of the neuroprotective and toxic effects of α7 nicotinic receptor activation in PC12 cells. *Brain Res* **830:**218–225.

Lindstrom JM (2003) Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. *Ann N Y Acad Sci* **998:**41–52.

Link CD (1995) Expression of human beta-amyloid peptide in transgenic *Caenorhabditis elegans. Proc Natl Acad Sci U S A* **92:**9368–9372.

Link CD (2006) *C. elegans* models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. *Exp Gerontol* **41:**1007–1013.

Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, and Sahagan BG (2003) Gene expression analysis in a transgenic *Caenorhabditis elegans* Alzheimer's disease model. *Neurobiol Aging* **24:**397–413.

Liu Q, Zhang J, Zhu H, Qin C, Chen Q, and Zhao B (2007) Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. *FASEB J* **21:**61–73.

Liu RY, Gu R, Qi XL, Zhang T, Zhao Y, He Y, Pei JJ, and Guan ZZ (2008) Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with β-amyloid peptide(1–42) and fed a high-cholesterol diet. *J Neurosci Res* **86:**183–193.

Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, and Nilsson LN (2006) The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. *Neurobiol Aging* **27:**67–77.

Loring JF, Wen X, Lee JM, Seilhamer J, and Somogyi R (2001) A gene expression profile of Alzheimer's disease. *DNA Cell Biol* **20:**683–695.

Lu Y, Lv Y, Ye Y, Wang Y, Hong Y, Fortini ME, Zhong Y, and Xie Z (2007) A role for presenilin in post-stress regulation: effects of presenilin mutations on Ca^{2+} currents in *Drosophila. FASEB J* **21:**2368–2378.

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, and Rogers J (1999) Soluble amyloid {beta} peptide concentration as a predictor of synaptic change in Alzheimer's disease. *Am J Pathol* **155:**853–862.

Luheshi LM, Tartaglia GG, Brorsson AC, Pawar AP, Watson IE, Chiti F, Vendruscolo M, Lomas DA, Dobson CM, and Crowther DC (2007) Systematic in vivo analysis of the intrinsic determinants of amyloid β pathogenicity. *PLoS Biology* **5:**e290.

Luo L, Tully T, and White K (1992) Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for APPL gene. *Neuron* **9:**595–605.

Lyness SA, Zarow C, and Chui HC (2003) Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: A meta-analysis. *Neurobiol Aging* **24:**1–23.

Martin SE, de Fiebre NE, and de Fiebre CM (2004) The α7 nicotinic acetylcholine receptor-selective antagonist, methyllycaconitine, partially protects against β-amyloid1–42 toxicity in primary neuron-enriched cultures. *Brain Research* **1022:**254–256.

Martín-Peña A, Acebes A, Rodríguez JR, Sorribes A, de Polavieja GG, Fernández-Fúnez P, and Ferrús A (2006) Age-independent synaptogenesis by phosphoinositide 3 kinase. *J Neurosci* **26:**10199–10208.

Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, et al. (1999) α4 But not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. *J Neurochem* **74:**1635–1640.

Marutle A, Unger C, Hellström-Lindahl E, Wang J, Puoliväli J, Tanila H, Nordberg A, and Zhang X (2002) Elevated levels of Abeta1–40 and Abeta1–42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice. *Neurosci Lett* **328:**269–272.

McGowan E, Eriksen J, and Hutton M (2006) A decade of modeling Alzheimer's disease in transgenic mice. *Trends Genet* **22:**281–289.

Meunier J, Ieni J, and Maurice T (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25–35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. *Br J Pharmacol* **149:**998–1012.

Mizukami K, Grayson DR, Ikonomovic MD, Sheffield R, and Armstrong DM (1998) GABAA receptor beta 2 and beta 3 subunits mRNA in the hippocampal formation of aged human brain with Alzheimer-related neuropathology. *Brain Res Mol Brain Res* **56:**268–272.

Moechars D, Dewachter I, Lorent K, Reversé D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, and Van Leuven F (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. *J Biol Chem* **274:**6483–6492.

Mousavi M and Nordberg A (2006) Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice

carrying genes coding for human AChE and beta-amyloid. *Int J Dev Neurosci* **24**:269–273.

Mousavi M, Hellström-Lindahl E, Guan ZZ, Shan KR, Ravid R, and Nordberg A (2003) Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. *Neuroscience* **122**:515–520.

Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, and McConlogue L (2000) High-level neuronal expression of Aβ 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *J Neurosci* **20**:4050–4058.

Nagele RG, D'Andrea MR, Anderson WJ, and Wang HY (2002) Intracellular accumulation of β-amyloid(1–42) in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimer's disease. *Neuroscience* **110**:199–211.

Nguyen HN, Rasmussen BA, and Perry DC (2003) Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. *J Pharmacol Exp Ther* **307**:1090–1097.

Nie H, Li Z, Lukas RJ, Shen Y, Song L, Wang X, and Yin M (2007) Construction of SH-EP1-α4β2-hAPP695 cell line and effects of nicotinic agonists on beta-amyloid in the cells. *Cell Mol Neurobiol* **28**:103–112.

Nuutinen S, Ekokoski E, Lahdensuo E, and Tuominen RK (2006) Nicotine-induced upregulation of human neuronal nicotinic alpha7-receptors is potentiated by modulation of cAMP and PKC in SH-EP1-halpha7 cells. *Eur J Pharmacol* **544**:21–30.

O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, and Williams ED (2007) α4β2 nicotinic receptor status in Alzheimer's disease using 123I–5IA-85380 single-photon-emission computed tomography. *J Neurol Neurosurg Psychiatry* **78**:356–362.

O'Neil JN, Mouton PR, Tizabi Y, Ottinger MA, Lei DL, Ingram DK, and Manaye KF (2007) Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. *J Chem Neuroanat* **34**:102–107.

Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, and LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular a[beta] and synaptic dysfunction. *Neuron* **39**:409–421.

Park HJ, Lee PH, Ahn YW, Choi YJ, Lee G, Lee DY, Chung ES, and Jin BK (2007) Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. *Eur J Neurosci* **26**:79–89.

Pettit DL, Shao Z, and Yakel JL (2001) β-Amyloid1–42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. *J Neurosci* **21**:RC120.

Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, Perry RH, Perry EK, and Wyper D (2004) Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-A-85380. *Neuropsychopharmacology* **29**:108–116.

Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, et al. (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in alzheimer disease. *Proc Natl Acad Sci U S A* **92**:12260–12264.

Price DL, Davis PB, Morris JC, and White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. *Neurobiol Aging* **12**:295–312.

Pym L, Kemp M, Raymond-Delpech V, Buckingham S, Boyd CA, and Sattelle D (2005) Subtype-specific actions of α-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (α7, α4β2, α3β4) expressed in *Xenopus laevis* oocytes. *Br J Pharmacol* **146**:964–971.

Pym LJ, Buckingham SD, Tsetlin V, Boyd CA, and Sattelle DB (2007) The Aβ(1–42)M35C mutated amyloid peptide Aβ(1–42) and the 25–35 fragment fail to mimic the subtype-specificity of actions on recombinant human nicotinic acetylcholine receptors (α7, α4β2, α3β4). *Neurosci Lett* **427**:28–33.

Qi XL, Nordberg A, Xiu J, and Guan ZZ (2007) The consequences of reducing expression of the α7 nicotinic receptor by RNA interference and of stimulating its activity with an α7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. *Neurochem Int* **51**:377–383.

Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jäggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Hölscher C, Mathews PM, and Jucker M (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Rep* **7**:940–946.

Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, and Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. *Ann Intern Med* **148**:379–397.

Rebolledo DL, Minniti AN, Grez PM, Fadic R, Kohn R, and Inestrosa NC (2008) Inclusion body myositis: a view from the *Caenorhabditis elegans* muscle. *Mol Neurobiol* **38**:178–198.

Ren K, Puig V, Papke RL, Itoh Y, Hughes JA, and Meyer EM (2005) Multiple calcium channels and kinases mediate α7 nicotinic receptor neuroprotection in PC12 cells. *J Neurochem* **94**:926–933.

Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, and Kemp JA (2003) PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. *J Neurosci* **23**:8989–9003.

Ritchie CW, Ames D, Clayton T, and Lai R (2004) Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. *Am J Geriatr Psychiatry* **12**:358–369.

Rosa AO, Egea J, Gandía L, López MG, and García AG (2006) Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation: involvement of the α7 nAChR subtype. *J Mol Neurosci* **30**:61–62.

Rowan MJ, Klyubin I, Wang Q, and Anwyl R (2004) Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity. *Exp Gerontol* **39**:1661–1667.

Roychaudhuri R, Yang M, Hoshi MM, and Teplow DB (2009) Amyloid β-protein assembly and Alzheimer's disease. *J Biol Chem* **284**:4749–4753.

Rusted JM, Newhouse PA, and Levin ED (2000) Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. *Behav Brain Res* **113**:121–129.

Ryan RE, Ross SA, Drago J, and Loiacono RE (2001) Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. *Br J Pharmacol* **132**:1650–1656.

Saavedra L, Mohamed A, Ma V, Kar S, and de Chaves EP (2007) Internalization of β-amyloid peptide by primary neurons in the absence of apolipoprotein E. *J Biol Chem* **282**:35722–35732.

Sabbagh MN, Reid RT, Hansen LA, Alford M, and Thal LJ (2001) Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. *J Neural Transm* **108**:1149–1157.

Sabbagh MN, Shah F, Reid RT, Sue L, Connor DJ, Peterson LK, and Beach TG (2006) Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. *Arch Neurol* **63**:1771–1776.

Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, et al. (2004) A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. *Am J Pathol* **165**:937–948.

Satoh Y, Endo S, Ikeda T, Yamada K, Ito M, Kuroki M, Hiramoto T, Imamura O, Kobayashi Y, Watanabe Y, et al. (2007) Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory. *J Neurosci* **27**:10765–10776.

Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, and Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. *Mol Pharmacol* **49**:1–6.

Severance EG and Yolken RH (2007) Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. *Genes Brain Behav* **7**:37–45.

Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* **14**:837–842.

Shaw S, Bencherif M, and Marrero MB (2002) Janus kinase 2, an early target of α7 nicotinic acetylcholine receptor-mediated neuroprotection against aβ-(1–42) amyloid. *J Biol Chem* **277**:44920–44924.

Shimohama S and Kihara T (2001) Nicotinic receptor-mediated protection against β-amyloid neurotoxicity. *Biol Psychiatry* **49**:233–239.

Shirazi SK and Wood JG (1993) The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. *Neuroreport* **4**:435–437.

Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G, and Nemeroff CB (1990) Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. *Proc Natl Acad Sci U S A* **87**:2452–2455.

Small DH, Maksel D, Kerr ML, Ng J, Hou X, Chu C, Mehrani H, Unabia S, Azari MF, Loiacono R, et al. (2007) The β-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor. *J Neurochem* **101**:1527–1538.

Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-β. *Nat Neurosci* **8**:1051–1058.

Spencer JP, Weil A, Hill K, Hussain I, Richardson JC, Cusdin FS, Chen YH, and Randall AD (2006) Transgenic mice over-expressing human β-amyloid have functional nicotinic α7 receptors. *Neuroscience* **137**:795–805.

Stevens TR, Krueger SR, Fitzsimonds RM, and Picciotto MR (2003) Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. *J Neurosci* **23**:10093–10099.

Strong R, Huang JS, Huang SS, Chung HD, Hale C, and Burke WJ (1991) Degeneration of the cholinergic innervation of the locus ceruleus in Alzheimer's disease. *Brain Res* **542**:23–28.

Struhl G and Greenwald I (1999) Presenilin is required for activity and nuclear access of Notch in *Drosophila*. *Nature* **398**:522–525.

Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. *Proc Natl Acad Sci U S A* **94**:13287–13292.

Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K, Andrä M, Matsubayashi H, Sakai N, Kohsaka S, et al. (2006) Microglial α7 nicotinic acetylcholine receptors drive a phospholipase C/IP₃ pathway and modulate the cell activation toward a neuroprotective role. *J Neurosci Res* **83**:1461–1470.

Svensson AL and Nordberg A (1999) Beta-estradiol attenuate amyloid β-peptide toxicity via nicotinic receptors. *Neuroreport* **10**:3485–3489.

Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, and Akaike A (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. *J Pharmacol Exp Ther* **306**:772–777.

Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, and Akaike A (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. *Neuropharmacology* **51**:474–486.

Tang X, Feng Y, and Ye K (2007) Src-family tyrosine kinase fyn phosphorylates phosphatidylinositol 3-kinase enhancer-activating Akt, preventing its apoptotic cleavage and promoting cell survival. *Cell Death Differ* **14**:368–377.

Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, and Perry E (2003) Alzheimer's disease is associated with a selective increase in α7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. *Glia* **41**:207–211.

Teplow DB (2006) Preparation of amyloid beta-protein for structural and functional studies. *Methods Enzymol* **413**:20–33.

Terzano S, Court JA, Fornasari D, Griffiths M, Spurden DP, Lloyd S, Perry RH,

Perry EK, and Clementi F (1998) Expression of the α3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. *Brain Res Mol Brain Res* **63:**72–78.

Thompson SA, Smith O, Linn DM, and Linn CL (2006) Acetylcholine neuroprotection against glutamate-induced excitotoxicity in adult pig retinal ganglion cells is partially mediated through α4 nAChRs. *Exp Eye Res* **83:**1135–1145.

Toborek M, Son KW, Pudelko A, King-Pospisil K, Wylegala E, and Malecki A (2007) ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons. *J Cell Biochem* **100:**279–292.

Torroja L, Chu H, Kotovsky I, and White K (1999) Neuronal overexpression of APPL, the *Drosophila* homologue of the amyloid precursor protein (APP), disrupts axonal transport. *Curr Biol* **9:**489–492.

Tozaki H, Matsumoto A, Kanno T, Nagai K, Nagata T, Yamamoto S, and Nishizaki T (2002) The inhibitory and facilitatory actions of amyloid-beta peptides on nicotinic ACh receptors and AMPA receptors. *Biochem Biophys Res Commun* **294:**42–45.

Trinh NH, Hoblyn J, Mohanty S, and Yaffe K (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer Disease: a meta-analysis. *JAMA* **289:**210–216.

Tsai JR, Chong IW, Chen CC, Lin SR, Sheu CC, and Hwang JJ (2006) Mitogen-activated protein kinase pathway was significantly activated in human bronchial epithelial cells by nicotine. *DNA Cell Biol* **25:**312–322.

Ubhi KK, Shaibah H, Newman TA, Shepherd D, and Mudher A (2007) A comparison of the neuronal dysfunction caused by *Drosophila* tau and human tau in a *Drosophila* model of tauopathies. *Invert Neurosci* 7:165–171.

van Groen T, Kiliaan AJ, and Kadish I (2006) Deposition of mouse amyloid [beta] in human APP/PS1 double and single AD model transgenic mice. *Neurobiol Dis* **23:**653–662.

Vasto S, Candore G, Aquino A, Bulati M, Balistreri CR, Grimaldi MP, Ditta V, Colonna-Romano G, Lio D, Vitello S, et al. (2006) The nACHR4 594C/T polymorphism in Alzheimer disease. *Rejuvenation Res* **9:**107–110.

Wada T, Naito M, Kenmochi H, Tsuneki H, and Sasaoka T (2007) Chronic nicotine exposure enhances insulin-induced mitogenic signaling via up-regulation of α7 nicotinic receptors in isolated rat aortic smooth muscle cells. *Endocrinology* **148:**790–799.

Wallace TA, Xia SL, and Sayeski PP (2005) Jak2 tyrosine kinase prevents angiotensin II-mediated inositol 1,4,5 trisphosphate receptor degradation. *Vascul Pharmacol* **43:**336–345.

Walsh DM and Selkoe DJ (2007) A beta oligomers—adecade of discovery. *J Neurochem* **101:**1172–1184.

Wang G, Zhang Y, Chen B, and Cheng J (2003a) Preliminary studies on Alzheimer's disease using cDNA microarrays. *Mech Ageing Dev* **124:**115–124.

Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, and Reitz AB (2000b) β-Amyloid1–42 binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. *J Biol Chem* **275:**5626–5632.

Wang HY, Lee DH, Davis CB, and Shank RP (2000a) Amyloid peptide Abeta(1–42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. *J Neurochem* **75:**1155–1161.

Wang HY, Li W, Benedetti NJ, and Lee DHS (2003b) α7 nicotinic acetylcholine receptors mediate β-amyloid peptide-induced tau protein phosphorylation. *J Biol Chem* **278:**31547–31553.

Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, and Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated *via* activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. *J Neurosci* **24:**3370–3378.

Warpman U and Nordberg A (1995) Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains. *Neuroreport* **6:**2419–2423.

Wehrwein E, Thompson SA, Coulibaly SF, Linn DM, and Linn CL (2004) Acetylcholine protection of adult pig retinal ganglion cells from glutamate-induced excitotoxicity. *Invest Ophthalmol Vis Sci* **45:**1531–1543.

Wevers A, Monteggia L, Nowacki S, Bloch W, Schütz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, et al. (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. *Eur J Neurosci* **11:**2551–2565.

Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I, et al. (2002) Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-β peptide exposure: involvement of Src family protein kinases. *J Neurosci* **22:**10–20.

Wu J, Khan GM, and Nichols RA (2007) Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. *Brain Res* **1182:**82–89.

Wu J, Kuo YP, George AA, Xu L, Hu J, and Lukas RJ (2004) β-Amyloid directly inhibits human α4β2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. *J Biol Chem* **279:**37842–37851.

Xiao Y, Shan KR, and Guan ZZ (2006) Effect of beta-amyloid peptides on alpha-7 nicotinic receptor status in astrocytes and neurons, and its relationship to pathogenesis of Alzheimer's disease. *Zhonghua Bing Li Xue Za Zhi* **35:**462–466.

Xin M and Deng X (2005) Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. *J Biol Chem* **280:**10781–10789.

Xiu J, Nordberg A, Zhang JT, and Guan ZZ (2005) Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the α7, α4 and β2 subunits in response to nanomolar concentrations of the β-amyloid peptide(1–42). *Neurochem Int* **47:**281–290.

Yao M, Nguyen TV, and Pike CJ (2005) β-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. *J Neurosci* **25:**1149–1158.

Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, and Coleman PD (2003) Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. *Neurobiol Dis* **12:**97–109.

Ye Y, Lukinova N, and Fortini ME (1999) Neurogenic phenotypes and altered Notch processing in *Drosophila* presenilin mutants. *Nature* **398:**525–529.

Yu WF, Guan ZZ, Bogdanovic N, and Nordberg A (2005) High selective expression of α7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. *Exp Neurol* **192:**215–225.

Yu WF, Nordberg A, Ravid R, and Guan ZZ (2003) Correlation of oxidative stress and the loss of the nicotinic receptor α4 subunit in the temporal cortex of patients with Alzheimer's disease. *Neurosci Lett* **338:**13–16.

Zeng H, Chen Q, and Zhao B (2004) Genistein ameliorates β-amyloid peptide (25–35)-induced hippocampal neuronal apoptosis. *Free Radical Biology and Medicine* **36:**180–188.

Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, and Van der Ploeg LH (1995) beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. *Cell* **81:**525–531.

Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, and Stern Y (2006) Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. *Neurology* **67:**998–1005.